CONSOLIDATED FINANCIAL STATEMENTS, REPORTS, SUPPLEMENTARY INFORMATION, AND SCHEDULE REQUIRED BY THE UNIFORM GUIDANCE

City of Hope Years Ended September 30, 2022 and 2021 With Reports of Independent Auditors

Ernst & Young LLP



Consolidated Financial Statements, Reports, Supplementary Information, and Schedule Required by the Uniform Guidance

Years Ended September 30, 2022 and 2021

Contents

1
4
6
8
10
66
68
73
83
85



Ernst & Young LLP Suite 500 725 South Figueroa Street Los Angeles, CA 90017-5418 Tel: +1 213 977 3200 Fax: +1 213 977 3152

Report of Independent Auditors

Management and The Board of Directors City of Hope

Report on the Audit of the Financial Statements

Opinion

We have audited the consolidated financial statements of City of Hope, which comprise the consolidated statements of financial position as of September 30, 2022 and 2021, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the City of Hope at September 30, 2022 and 2021, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of City of Hope and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

1



In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about City of Hope's ability to continue as a going concern for one year after the date that the financial statements are issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether
 due to fraud or error, and design and perform audit procedures responsive to those risks.
 Such procedures include examining, on a test basis, evidence regarding the amounts and
 disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of City of Hope's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about City of Hope's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

2306-4265642



Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. We have not performed any procedures with respect to the audited financial statements subsequent to December 16, 2022. The Schedule of Expenditures of Federal Awards, as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated December 16, 2022 on our consideration of City of Hope's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of City of Hope's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering City of Hope's internal control over financial reporting and compliance.

Ernst + Young LLP

December 16, 2022, except for our report on the Schedule of Expenditures of Federal Awards, for which the date is June 30, 2023

3 2306-4265642

Consolidated Statements of Financial Position (In Thousands)

	September 30			
		2022		2021
Assets				
Current assets:				
Cash and cash equivalents	\$	232,284	\$	262,033
Investments		1,555,739		2,166,955
Self-insurance trust funds		3,959		3,608
Patient accounts receivable		464,078		319,133
Grants and other receivables		174,032		156,100
Current portion of donor-restricted unconditional				
promises to give, net		48,209		38,159
Prepaid and other		117,059		74,235
Total current assets		2,595,360		3,020,223
Property and equipment, net		2,052,723		1,412,291
Right-of-use finance lease assets		46,363		49,989
Right-of-use operating lease assets		188,390		151,314
Other assets:				
Investments held for long-term purposes		18,892		38,750
Board-designated assets		1,050,182		1,229,844
Bond trust funds		160,785		245,730
With donor restrictions:				
Investments		667,392		682,583
Unconditional promises to give, net		145,100		96,328
Contributions receivable from annuity and split-interest				
agreements, net		106,867		114,662
Other		20,321		9,655
Intangible assets		22,528		10,427
Goodwill		77,426		88,086
Other long-term assets		76,899		69,331
Total other assets		2,346,392		2,585,396
Total assets	\$	7,229,228	\$	7,219,213

Consolidated Statements of Financial Position (In Thousands)

	September 30			r 30
		2022		2021
Liabilities and net assets				
Current liabilities:				
Accounts payable and other accrued liabilities	\$	470,537	\$	317,273
Accrued salaries, wages, and employee benefits		150,601		149,071
Long-term debt, current portion		7,190		6,940
Right-of-use finance leases, current portion		8,375		7,338
Right-of-use operating leases, current portion		27,541		19,480
Due to third-party payors		42,620		12,436
Contract liabilities		15,526		118,817
Total current liabilities		722,390		631,355
Long-term debt, net of current portion		1,934,846		1,295,386
Right-of-use finance leases, net of current portion		45,808		50,523
Right-of-use operating leases, net of current portion		163,381		143,704
Annuity and split-interest agreement obligations		27,854		27,707
Interest rate swaps		2,232		19,497
Other		69,352		82,341
Total liabilities		2,965,863		2,250,513
Net assets: Without donor restrictions:				
Controlling interests		3,276,446		4,026,274
Noncontrolling interests		29,277		29,621
With donor restrictions		957,642		912,805
Total net assets		4,263,365		4,968,700
Total liabilities and net assets	<u> </u>	7,229,228	\$	7,219,213
Total Hauthurs and het assets	<u> </u>	1,447,440	φ	1,417,413

Consolidated Statement of Activities (In Thousands)

Year Ended September 30, 2022

	Without Donor			n Donor		
	<u>R</u>	estrictions	Rest	rictions		Total
Revenues, gains, and other support:	Φ.	2 025 452	Φ.		Φ.	2 025 452
Net patient service revenues	\$	2,925,453	\$	_	\$	2,925,453
Research grants, contracts, and clinical trials		215,970		-		215,970
Contributions		55,778		176,209		231,987
Investment income		199,860		41,822		241,682
Net unrealized loss on investments		(576,869)		(74,357)		(651,226)
Royalty and licensing revenue		19,916		_		19,916
Other revenue		80,815				80,815
Total revenues, gains, and other support		2,920,923		143,674		3,064,597
Net assets released from restrictions		98,837		(98,837)		
Total revenues, gains, and other support		3,019,760		44,837		3,064,597
Expenses:						
Salaries, wages, and employee benefits		1,360,040		_		1,360,040
Purchased services and professional fees		778,420		_		778,420
Supplies and pharmaceuticals		1,102,522		_		1,102,522
Royalty sharing		6,416		_		6,416
Interest, including changes in fair						
value of swap agreements		15,832		_		15,832
Depreciation and amortization		194,770		_		194,770
Hospital provider fee		37,730		_		37,730
Other expense		272,740		_		272,740
Total expenses		3,768,470		_		3,768,470
(Deficiency) excess of revenues, gains, and other						
support over expenses		(748,710)		44,837		(703,873)
Distribution to non controlling interest		(1,462)		_		(1,462)
Changes in net assets		(750,172)		44,837		(705,335)
Net assets, beginning of year		4,055,895		912,805		4,968,700
Net assets, end of year	\$	3,305,723	\$	957,642	\$	4,263,365

Consolidated Statement of Activities

(In Thousands)

Year Ended September 30, 2021

	Without Donor Restrictions		With Donor Restrictions		Total
Revenues, gains, and other support:					
Net patient service revenues	\$ 1,	851,375	\$	_	\$ 1,851,375
Research grants, contracts, and clinical trials		183,467		_	183,467
Contributions		37,461	2.	38,451	275,912
Investment income		258,455	4	49,659	308,114
Net unrealized gain on investments		389,256	:	50,880	440,136
Royalty and licensing revenue		114,247		_	114,247
Gain on sale of subsidiary		77,327			77,327
Other revenue		87,132		265	87,397
Total revenues, gains, and other support	2,	,998,720	3.	39,255	3,337,975
Net assets released from restrictions		111,450	(1	11,450)	_
Total revenues, gains, and other support	3.	,110,170	22	27,805	3,337,975
Expenses:					
Salaries, wages, and employee benefits	1,	,017,591		_	1,017,591
Purchased services and professional fees		551,259		_	551,259
Supplies and pharmaceuticals		604,431		_	604,431
Royalty sharing		36,606		_	36,606
Interest, including changes in fair					
value of swap agreements		32,313		_	32,313
Depreciation and amortization		153,399		_	153,399
Hospital provider fee		26,493		_	26,493
Other expense		128,205		_	128,205
Total expenses	2	,550,297		_	2,550,297
Excess of revenues, gains, and other					
support over expenses		559,873	22	27,805	787,678
Changes in net assets		559,873	22	27,805	787,678
Net assets, beginning of year	3	496,022	6	85,000	4,181,022
Net assets, end of year		055,895	\$ 9	12,805	\$ 4,968,700

Consolidated Statements of Cash Flows

(In Thousands)

	Year Ended September 30		
	2022	2021	
Operating activities			
Changes in net assets	\$ (705,335) \$	787,678	
Adjustments to reconcile changes in net assets to net cash provided by			
operating activities:			
Depreciation and amortization expense	180,724	146,105	
Amortization of goodwill and other intangibles	14,046	7,294	
Amortization of bond costs, discount, and premium	(2,940)	(2,990)	
Amortization of right-of-use operating lease assets	25,974	15,286	
Distribution to noncontrolling interest	1,462	_	
Net unrealized loss (gain) on investments	651,226	(440,136)	
Change in value of interest rate swaps	(34,416)	(10,882)	
Contribution proceeds restricted for endowment	(29,105)	(15,608)	
Gain on sale of subsidiary	_	(77,327)	
Other	_	656	
Changes in assets and liabilities:			
Patient accounts receivable	(24,727)	(61,765)	
Grants and other receivables	(8,125)	(1,714)	
Unconditional promises to give, net	(58,822)	(19,039)	
Contributions receivable from annuity and split-interest agreements, net	7,795	(99,534)	
Other assets	(10,722)	(14,894)	
Accounts payable and other accrued liabilities	63,229	51,202	
Accrued salaries, wages, and employee benefits	(14,388)	(12,431)	
Annuity and split-interest agreement obligations	147	7,858	
Operating lease liabilities	(26,657)	(12,556)	
Other liabilities	 (140,540)	37,008	
Net cash (used in) provided by operating activities before net sales of			
trading investments	(111,174)	284,211	
Net sales of trading investments	 629,881	285,756	
Net cash provided by operating activities	518,707	569,967	
Investing activities			
Acquisition of community practice sites	_	(57,102)	
Proceeds on sale of subsidiary	_	72,000	
Proceeds from sale of Exact Sciences common stock from Ashion Analytics sale	_	12,116	
Acquisition of business, net of cash acquired	(343,970)	_	
(Increase) decrease in notes receivable	(633)	690	
Additions to property and equipment	(493,286)	(365,879)	
Proceeds from sale of contributed real property held for sale	47	240	
Net purchases of alternative investments	 (305,530)	(233,719)	
Net cash used in investing activities	(1,143,372)	(571,654)	

Consolidated Statements of Cash Flows (continued) (In Thousands)

	Year Ended September 30			
		2022	2021	
Financing activities				
Repayments of line of credit	\$	- \$	(450,000)	
Proceeds from long-term debt borrowing, net		650,000	4,500	
Issuance cost for Bridge Loan		(821)	_	
Principal payments on long-term debt		(6,840)	(7,143)	
Principal payments on finance leases		(10,009)	(7,363)	
Distribution to noncontrolling interest		(1,462)	_	
Contribution proceeds restricted for endowment		29,105	15,608	
Net cash provided by (used in) financing activities		659,973	(444,398)	
Net increase (decrease) in cash, cash equivalents, and restricted cash		35,306	(446,085)	
Cash, cash equivalents, and restricted cash beginning of year		325,763	771,848	
Cash, cash equivalents, and restricted cash end of year	\$	361,069 \$		
Supplemental disclosure of cash flow information				
Interest paid during the year (net of capitalized interest)	\$	52,377 \$	41,909	
Supplemental disclosure of noncash activity				
Finance lease obligation	_\$	4,303 \$	610	
Operating lease obligation	\$	51,691 \$	56,782	
Noncash stock received	\$	- \$	15,310	
Additions to property and equipment included in accounts				
payable and accrued liabilities	\$	76,375 \$	76,433	

Notes to Consolidated Financial Statements (Dollar Amounts Expressed in Thousands)

September 30, 2022

1. Organization

City of Hope, a California nonprofit public benefit corporation, with its principal offices located in Duarte, California, is the development organization of City of Hope National Medical Center (the "Center"), City of Hope Medical Foundation (the "Foundation"), and Beckman Research Institute of the City of Hope (the "Institute") (collectively, the "Obligated Group"), the Translational Genomics Research Institute and its Affiliates ("TGen"), Southern California Radiation Oncology, LLC ("SCRO"), AccessHope, LLC ("AH"), City of Hope Auxiliaries (the "Auxiliaries") and COH HoldCo Inc. ("HoldCo"), the parent of Cancer Treatment Centers of America entities ("CTCA Entities") (collectively, the "Affiliated Group"). These entities represent the consolidated City of Hope organization (collectively referred to as "City of Hope"). City of Hope's management and staff coordinate the fundraising activities of the many volunteers and donors needed to support the patient care and research mission of City of Hope.

The Center is a California nonprofit public benefit corporation treating primarily cancer and other life-threatening diseases. The Center is currently licensed to operate at a capacity of 234 beds. City of Hope is the sole corporate member of the Center.

The Foundation is a California nonprofit public benefit corporation organized as part of a coordinated health care delivery system to provide teaching, education, and research services in support of the Center and the Institute. The Foundation also owns and/or operates outpatient clinic facilities that provide an extensive range of medical care and treatment. City of Hope is the sole corporate member of the Foundation.

The Foundation has entered into a professional services agreement with City of Hope Medical Group ("COHMG"), an unconsolidated medical group. Under the terms of the professional services agreement, COHMG physicians provide exclusive patient care services and academic services, such as teaching, administration, and research, to the Foundation. As part of City of Hope's goal of creating greater integration and coordination of City of Hope's patient care, research, and educational services, the Foundation provides for, or arranges for, the provision of certain patient care and on-call coverage services and teaching, administration, and research for the operations and activities of the Center pursuant to an agreement between the Foundation and the Center. The professional fee revenue and expense associated with the contract between the Foundation and the Center are eliminated in consolidation.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

1. Organization (continued)

Pursuant to the professional services agreement, COHMG assigns to the Foundation the right to bill and collect for professional services rendered by COHMG physicians and other professional employees, and the Foundation contracts directly with payors for the provision of patient care services. Accordingly, net patient service revenues for the Foundation include amounts for services provided by COHMG physicians on behalf of the Foundation.

The Institute is a California nonprofit public benefit corporation that owns and operates several major research facilities on or near City of Hope's main campus. The Institute conducts basic scientific research in support of, and in conjunction with, the patient care activities of the Center and the Foundation. City of Hope is the sole corporate member of the Institute.

TGen, located in Phoenix, Arizona, is an Arizona nonprofit public benefit corporation that translates genomic discoveries into advances in human health. TGen employs innovative advances arising from the Human Genome Project and applies them to the development of diagnostics. The accounts of TGen include the assets, liabilities, and results of operations of TGen Foundation and certain other controlled entities that were created to support TGen through its various functions. City of Hope is the sole corporate member of TGen.

SCRO, a California for-profit joint venture, was formed on March 30, 2018 between the Foundation and Vantage Oncology Treatment Centers, LLC ("Vantage") to manage and provide services to nine freestanding radiation therapy centers in Southern California. The Foundation owns 50.1% and Vantage owns 49.9% of SCRO. City of Hope consolidates SCRO, due to the Foundation's ability to exercise control as the result of its majority voting interest.

AH, located in Irwindale, California, is a Delaware limited liability company that provides for or arranges for the provision of certain oncology-related consultative, advisory, and support services designed to address the specific cancer needs of patients, improve care outcomes, and drive value to employers and payors throughout the United States. City of Hope owns a majority membership interest in AH. City of Hope consolidates AH, because of its ability to exercise control through its majority voting interest.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

1. Organization (continued)

During the fiscal year ended September 30, 2022, the Auxiliaries, located throughout the United States, as nonprofit public benefit unincorporated associations that coordinate fundraising activities to support the mission of City of Hope, ceased operating as organizations separate from City of Hope. Those revenues (\$23,900 and \$16,500 during fiscal years ended September 30, 2022 and 2021, respectively) are now reported as City of Hope's revenues and are included within the Obligated Group. This classification change has no impact at the consolidated City of Hope level.

HoldCo, a nonprofit Delaware corporation of which City of Hope is the sole corporate member, consolidates the CTCA Entities which were acquired on February 1, 2022. See Note 3, Business Combinations, for further details. HoldCo is the parent organization of the CTCA Entities and supports the activities of three hospitals, located in Arizona, Georgia, and Illinois, that provide comprehensive cancer care to patients, together with the associated physician groups, outpatient clinics, and intellectual property.

Principles of Consolidation

The consolidated financial statements of City of Hope have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). All intercompany accounts are eliminated in consolidation.

Reclassifications

Certain reclassifications have been made to prior year amounts to conform to the current year presentation. In the consolidated statement of activities, \$13,956 of specialty pharmacy revenue earned in fiscal year 2021 related to the Foundation was reclassified from other revenue to net patient service revenues. Further, in the consolidated statement of financial position, \$5,945 of accounts receivable related to specialty pharmacy for the Foundation as of September 30, 2021 was reclassified from grants and other receivables to patient accounts receivable.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies

New Accounting Standards Adopted

In August 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2018-15, Intangibles – Goodwill and Other — Internal-Use Software ("Subtopic 350-40"), Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The ASU is effective for annual periods beginning after December 15, 2020. The ASU was adopted by City of Hope using the prospective transition method for the fiscal year ended September 30, 2022 with an immaterial impact on its consolidated financial statements.

In September 2020, the FASB issued ASU 2020-07, *Not-for-Profit Entities (Topic 958): Presentation and Disclosure by Not-for-Profit Entities for Contributed Nonfinancial Assets.* This ASU enhances presentation and disclosure requirements for not-for-profit entities to increase the transparency in reporting contributed nonfinancial assets. The ASU is effective for annual periods beginning after June 15, 2021. City of Hope adopted this ASU effective for the fiscal year ended September 30, 2022, using the retrospective transition method, with no impact to its consolidated financial statements for the years presented.

New Accounting Standards Not Yet Adopted

In March 2020, the FASB issued ASU 2020-04, *Reference Rate Reform (Topic 848)*, to provide optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by the discontinuation of LIBOR or by another reference rate expected to be discontinued because of reference rate reform. The guidance was effective beginning March 12, 2020 and can be applied prospectively through December 31, 2022. In January 2021, the FASB issued ASU 2021-01 to clarify the scope and application of the original guidance. City of Hope plans to adopt ASU 2020-04 and ASU 2021-01 when LIBOR is discontinued. City of Hope is currently evaluating the potential impact of adopting this guidance on its consolidated financial statements.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

In October 2021, the FASB issued ASU 2021-08, *Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.* ASU 2021-08 requires that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, *Revenue from Contracts with Customers.* The ASU aligns the business combination accounting with the subsequent accounting for contract assets and liabilities under Accounting Standards Codification ("ASC") 606. The amendments are effective for fiscal years beginning after December 15, 2023 and applied prospectively. City of Hope is evaluating the effect of this standard on its consolidated financial statements.

Use of Estimates

The preparation of City of Hope's consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Principal areas requiring the use of estimates include recognition of net patient service revenues, which includes contractual discounts and adjustments, price concessions, and charity care; valuation of unconditional promises to give; cost report settlements and amounts due to/from third-party payors; valuation of annuity and split-interest agreement obligations; fair value of interest rate swap agreements; fair value of treasury rate locks; fair value of business combinations; impairment of goodwill and other intangibles; and self-insured liabilities. Actual results could differ from those estimates and the amounts could be material to the consolidated financial statements.

Performance Indicator

Management considers changes in net assets to be the performance indicator.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

Cash and Cash Equivalents

Cash and cash equivalents reflect all unrestricted cash and cash equivalents that include highly liquid investments with original maturities of three months or less from the date of purchase and exclude amounts whose use is limited under contractual or donor agreements or are held in investment portfolios that are included in investments and investments held for long-term purposes on the consolidated statements of financial position. Amounts within restricted cash include cash and cash equivalents held within bond trust funds and represent funds set aside based on contractual arrangements.

Cash and cash equivalents, including restricted cash, that are held as a component of donor-restricted assets are reflected in bond trust funds on the accompanying consolidated statements of financial position. The reconciliation of cash and cash equivalents, and restricted cash within the consolidated statements of financial position that comprise the amount reported on the consolidated statements of cash flows as of September 30 is as follows:

	2022			2021
Cash and cash equivalents	\$	232,284	\$	262,033
Restricted cash in bond trust funds		128,785		63,730
Total cash, cash equivalents, and restricted cash	\$	361,069	\$	325,763

Investments

Investments in equity securities with readily determinable fair values and all investments in debt securities are measured at fair value on the consolidated statements of financial position (see Note 4, Fair Value of Financial Instruments). These equity and debt securities are designated as trading securities, since the investments are externally managed within the guidelines of City of Hope's investment policy. Fair value is established based on quoted prices from recognized security exchanges. Accordingly, the change in unrealized gains and losses on investments is reported within the (deficiency) excess of revenues, gains, and other support over expenses on the consolidated statements of activities. Investment transactions are recorded on a settlement date basis.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

Investment income or loss on equity and debt securities included in net assets with donor restrictions (including realized gains and losses on investments, interest, and dividends) is reported in revenues without donor restrictions, unless the income or loss is specifically restricted by the donor or by law.

City of Hope's alternative investments consist of equity commingled funds that invest primarily in marketable securities and fund limited partnerships. Various strategies seek to achieve attractive risk-adjusted returns across public and private equity and debt securities, derivatives, private companies, venture capital, real estate, etc. These alternative investments may invest in both registered and non-registered securities in the U.S. and globally, with exposure to both emerging and developed markets.

City of Hope's hedge fund investments consist of direct and multi-manager "hedge fund of fund" investments. Strategies include long/short equity, long/short credit, and other strategies. Investments in hedge funds have limited liquidity and may be subject to various lockup periods, redemption fees, and notice requirements. Hedge funds typically reserve the right to reduce or suspend redemptions (gating event) and to satisfy redemptions by making distributions in kind, under certain circumstances. Additionally, hedge funds may hold, directly or indirectly, side-pocket investments where no redemptions are permitted until such investments are liquidated or deemed realized. Redemption periods range monthly, quarterly, or annually with notice requirements between 30 to 90 days. City of Hope also invests in fund limited partnerships with private equity-like terms, including capital calls, during its investment period. These select funds, which are currently opportunistic credit strategies, are classified as hedge funds.

City of Hope's private equity investments consist of fund limited partnerships. Strategies include buyout, venture/growth capital, debt, and secondary private equity. Fund terms are typically ten years or greater. City of Hope may not withdraw, sell, assign, or transfer its interests in these funds, except in certain, very limited circumstances, subject to consent by the general partners of the funds.

City of Hope's public and private real asset investments consist of fund limited partnerships that may invest in equity and debt of commercial, industrial, and residential properties, and energy and related companies. Fund terms are typically ten years or greater and City of Hope may not withdraw or sell, assign, or transfer its interests in these funds except in certain very limited circumstances, subject to consent by the general partners of the funds.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

City of Hope's commitments to fund limited partnerships are generally structured as drawdown funds, to which City of Hope funds future capital calls as investments are made over the investment period as established in the respective fund terms. Based upon the most recent available information, the outstanding unfunded commitments as of September 30 were as follows:

	2022			2021	
Private equity	\$	302,200	\$	357,100	
Private real assets:					
Real estate		184,200		195,300	
Natural resources		15,200		20,800	
Total unfunded commitments	\$	501,600	\$	573,200	

City of Hope accounts for its ownership interests in alternative investments at fair value, under which the net asset value is used as a practical expedient to fair value on the accompanying consolidated statements of financial position and its changes in fair value and share of earnings are included in net unrealized gain or loss on investments on the consolidated statements of activities.

During the fiscal year ended September 30, 2022, City of Hope executed three treasury rate lock agreements on March 2, 2022, March 15, 2022, and April 12, 2022, with an aggregate notional amount of \$261,000 to lock in the underlying U.S. Treasury interest rate component of the interest rate payments on anticipated debt issuances. These treasury lock agreements have an average fixed rate of 2.56% and are scheduled to terminate on November 10, 2022. As of September 30, 2022, the fair value of the treasury rate locks were \$49,418 (see Note 4, Fair Value of Financial Instruments), and included within current assets, investments on the accompanying consolidated statements of financial position. The treasury rate locks were not hedged, so the changes in fair value are recorded within net unrealized gain or loss on investments in the accompanying consolidated statements of activities. The treasury rate locks were subsequently terminated as scheduled (see Note 20, Subsequent Events).

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

Patient Accounts Receivable and Patient Service Revenue

City of Hope receives payments for services rendered to patients from federal and state governmental programs, mainly Medicare and Medicaid, privately sponsored contracted plans (including commercial, Medicare Advantage, and Medicaid managed care) for which payment is made based on terms defined under formal contracts, and other payors. City of Hope recognizes that revenues and receivables from government agencies are significant to its operations, but it does not believe there are significant credit risks associated with these government agencies. There are no significant concentrations of revenues or receivables from any payor that would subject City of Hope to any significant credit risks in the collection of patient accounts receivable.

Changes in general economic conditions, patient accounting operations, payor mix, or federal or state governmental health care coverage could affect the collection of patient accounts receivable, cash flows, and results of operations.

Net patient service revenues are reported at the amount that reflects the consideration to which City of Hope expects to be entitled in exchange for providing patient care. These amounts, representing transaction price, are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlement of third-party payor audits or reviews. Patients and third-party payors are billed after the services are performed and/or the patient is discharged from the facility. City of Hope recognizes revenue as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by City of Hope. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to the total expected. City of Hope believes this method provides a reasonable depiction of the transfer of services over the term of the performance obligation based on the inputs necessary to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients receiving inpatient care services in the Center and the CTCA Entities and the performance obligation is measured from admission to the hospital to the point when it is no longer required to provide goods or services to the patient for that admission, which is generally at the time of discharge.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

Substantially all performance obligations relate to contracts with a duration of less than one year; City of Hope has elected to continue to apply the optional exemption provided in ASC 606-10-50-14(a) and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are primarily related to inpatient care services whose performance obligation for these contracts is generally completed when the patients are discharged, which often occurs within weeks of the end of the reporting period.

City of Hope has agreements with third-party payors that provide for payments to City of Hope at amounts different from established rates. Transaction prices are determined based on standard charges for goods and services provided to patients and are reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the City of Hope's charity policies, and/or implicit price concessions based on historical collection experience.

Medicare and Medicaid reimburses the Center and the CTCA Entities for cost-reimbursable items at an interim rate, and final settlements are determined after an audit of the related annual cost reports by the Medicare and Medicaid fiscal intermediary. Estimated provisions to approximate the full expected settlements after review by the intermediary are included in the accompanying consolidated financial statements.

Expected settlement amounts are included in due to third-party payors on the consolidated statements of financial position. Estimation differences between final settlements and amounts accrued in previous years are reported as adjustments of the current year's net patient service revenues. In the opinion of management, adequate provision has been made for any adjustments that might result from this review. During the fiscal years ended September 30, 2022 and 2021, the Center received information requiring changes in its estimates of settlements due for certain open cost report years and appeals. The Center recorded increases to net patient service revenues totaling \$16,542 and \$6,520 for the fiscal years ended September 30, 2022 and 2021, respectively.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

Hospital Fee Programs

The state of California enacted legislation for a hospital fee program to fund certain Medicaid coverage expansions. The program charges hospitals a quality assurance fee that is used to obtain federal matching funds for Medicaid with the proceeds redistributed as supplemental payments to California hospitals that treat Medicaid patients. There were two programs with activity for the fiscal years ended September 30, 2022 and 2021: (1) a 30-month hospital fee program covering the periods from July 1, 2019 through December 31, 2021, and (2) a 12-month hospital fee program covering the periods from January 1, 2022 through December 31, 2022.

The Center also entered into various enforceable pledge agreements with the California Health Foundation and Trust ("CHFT"), agreeing to make contributions to CHFT based on a predescribed calculation methodology. These funds will be used by CHFT to support charitable activities at various independent hospitals and hospital/health systems in California, including measures to alleviate distortions, interruptions, and disparities potentially resulting from short-term changes in government health care reimbursement programs, including the hospital fee to be imposed on hospitals under the hospital fee program.

City of Hope recognized net patient service revenue and hospital program expenses associated with the Hospital Assessment Program (HAP) for the State of Illinois.

City of Hope recognized \$91,722 and \$87,185 in net patient service revenues related to the hospital fee programs on the accompanying consolidated statements of activities for the fiscal years ended September 30, 2022 and 2021, respectively. Additionally, City of Hope recognized \$37,730 and \$26,493 in expenses related to the hospital fee programs for the fiscal years ended September 30, 2022 and 2021, respectively, which has been reflected in hospital provider fee expense on the accompanying consolidated statements of activities.

As of September 30, 2022 and 2021, \$71,395 and \$48,737 of hospital fee programs receivables is included in grants and other receivables, respectively, and \$30,426 and \$19,936 of hospital fee programs payables is included in accounts payable and other accrued liabilities, respectively, on the accompanying consolidated statements of financial position.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

Property and Equipment

Property and equipment are stated at cost when purchased or at fair market value on the contribution date in the case of a donation. When property and equipment are sold or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in other expense on the accompanying consolidated statements of activities. The costs of normal maintenance, repairs, and minor replacements are charged to expense when incurred.

City of Hope provides for depreciation and amortization using the straight-line method over the following estimated useful lives:

Buildings and improvements	7 to 40 years
Equipment and furniture	3 to 15 years
Software	3 to 5 years

Leasehold improvements are amortized on a straight-line basis over the term of the lease or estimated useful life, whichever is shorter. Finance lease amortization is included with depreciation and amortization (see Note 15, Leases).

City of Hope reviews long-lived assets for impairment when events or changes in business conditions indicate that their carrying value may not be recoverable. Impairment is considered when the associated expected undiscounted cash flows are less than the carrying value and the assets will be written down to fair value at that time. Fair value is the present value of the associated cash flows. As of September 30, 2022 and 2021, no impairment was recorded on long-lived assets.

Interest and Capitalized Interest

Total interest cost incurred on all financing vehicles (excluding changes in fair value of interest rate swap agreements) totaled \$68,886 and \$63,589 in 2022 and 2021, respectively. Interest cost incurred on borrowed funds during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets. For the fiscal years ended September 30, 2022 and 2021, capitalized interest income of \$9,732 and \$4,878, respectively, was earned on the 2019 bonds. Capitalized interest expense incurred during the same years was \$18,637 and \$20,394, respectively.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

Intangible Assets and Goodwill

Intangible assets consist of the following as of September 30:

				2022			
		Gross				Net	Estimated
	C	arrying		cumulated		Carrying	Useful Life
		Value	An	nortization		Value	(in Years)
Intangible assets subject to amortization:							
Tradename	\$	24,626	\$	(10,542)	\$	14,084	2 to 7
Noncompete agreement		188		(110)		78	2
Electronic medical records		2,280		(2,280)		-	10
Favorable leasehold interests		1,280		(747)		533	8
Intellectual property and research and		4.600		(7(7)		2 022	10
development costs related to TARDIS		4,600		(767)		3,833	10
Total intangible assets subject to amortization		32,974		(14,446)		18,528	
Intensible assets not subject to amortization							
Intangible assets not subject to amortization: Tradename		4,000				4,000	Indefinite
Total intangible assets not subject to amortization		4,000		_ _		4,000	indefinite
Total intaligible assets not subject to amortization	\$	36,974	\$	(14,446)	\$	22,528	
	Ψ	30,774	Ψ	(14,440)	Ψ	22,320	
				2021			
		Gross		2021		Net	Estimated
	_	Gross Sarrying	Ac	2021		Net Carrying	Estimated Useful Life
Intangible assets subject to amortization:		arrying		cumulated		Carrying	Useful Life
Tradename	\$	Carrying Value 9,026		ecumulated nortization (7,710)	\$	Carrying	Useful Life
Tradename Noncompete agreement		Value 9,026 188	An	ccumulated nortization (7,710) (16)	\$	Carrying Value	Useful Life (in Years) 2 to 7 2
Tradename Noncompete agreement Electronic medical records		9,026 188 2,280	An	(7,710) (16) (2,280)	\$	Carrying Value 1,316 172	Useful Life (in Years) 2 to 7 2 10
Tradename Noncompete agreement Electronic medical records Favorable leasehold interests		Value 9,026 188	An	ccumulated nortization (7,710) (16)	\$	Carrying Value	Useful Life (in Years) 2 to 7 2
Tradename Noncompete agreement Electronic medical records Favorable leasehold interests Intellectual property and research and		9,026 188 2,280 1,280	An	(7,710) (16) (2,280) (634)	\$	Carrying Value 1,316 172 - 646	Useful Life (in Years) 2 to 7 2 10 8
Tradename Noncompete agreement Electronic medical records Favorable leasehold interests Intellectual property and research and development costs related to TARDIS		9,026 188 2,280 1,280	An	(7,710) (16) (2,280) (634)	\$	Carrying Value 1,316 172 - 646 4,293	Useful Life (in Years) 2 to 7 2 10
Tradename Noncompete agreement Electronic medical records Favorable leasehold interests Intellectual property and research and		9,026 188 2,280 1,280	An	(7,710) (16) (2,280) (634)	\$	Carrying Value 1,316 172 - 646	Useful Life (in Years) 2 to 7 2 10 8
Tradename Noncompete agreement Electronic medical records Favorable leasehold interests Intellectual property and research and development costs related to TARDIS Total intangible assets subject to amortization		9,026 188 2,280 1,280	An	(7,710) (16) (2,280) (634)	\$	Carrying Value 1,316 172 - 646 4,293	Useful Life (in Years) 2 to 7 2 10 8
Tradename Noncompete agreement Electronic medical records Favorable leasehold interests Intellectual property and research and development costs related to TARDIS Total intangible assets subject to amortization Intangible assets not subject to amortization:		9,026 188 2,280 1,280 4,600 17,374	An	(7,710) (16) (2,280) (634)	\$	Carrying Value 1,316 172 - 646 4,293 6,427	2 to 7 2 10 8
Tradename Noncompete agreement Electronic medical records Favorable leasehold interests Intellectual property and research and development costs related to TARDIS Total intangible assets subject to amortization Intangible assets not subject to amortization: Tradename		9,026 188 2,280 1,280 4,600 17,374	An	(7,710) (16) (2,280) (634)	\$	Carrying Value 1,316 172 - 646 4,293 6,427 4,000	Useful Life (in Years) 2 to 7 2 10 8
Tradename Noncompete agreement Electronic medical records Favorable leasehold interests Intellectual property and research and development costs related to TARDIS Total intangible assets subject to amortization Intangible assets not subject to amortization:		9,026 188 2,280 1,280 4,600 17,374	An	(7,710) (16) (2,280) (634)	\$	Carrying Value 1,316 172 - 646 4,293 6,427	2 to 7 2 10 8

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

Under ASC 350, *Intangibles – Goodwill and Other ("ASU Topic 350")*, goodwill and these intangibles are subject to an impairment assessment when significant indicators of impairment exist. There was no indication of an impairment in value for goodwill or intangibles as of September 30, 2022.

City of Hope recorded \$3,386 and \$594 of amortization expense for intangible assets and \$113 and \$151 in rent expense for favorable leasehold interests during the fiscal years ended September 30, 2022 and 2021, respectively. During the fiscal year ended September 30, 2021, TGen began amortizing intangible assets for intellectual property and research and development costs related to TGen's proprietary Targeted Digital Sequencing ("TARDIS") blood biopsy technology, which was previously not subject to amortization.

Goodwill represents the excess of the consideration paid over the fair value of the net assets acquired, including identifiable intangible assets. City of Hope amortizes goodwill on a straight-line basis over ten years and performs a one-step impairment test at the entity level only when an impairment indicator exists. The accumulated goodwill amortization as of September 30, 2022 and 2021 was \$29,173 and \$18,513, respectively.

The following table provides a rollforward of goodwill for the fiscal years ended September 30:

		2022	2021
Balance, beginning of fiscal year	•	88,086 \$	47,254
	Þ	οο,υου φ	,
Acquisitions (see Note 3, Business Combinations)		_	47,532
Amortization		(10,660)	(6,700)
Balance, end of fiscal year	\$	77,426 \$	88,086

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

Future amortization of intangible assets subject to amortization for subsequent fiscal years is reflected below:

	_ (Goodwill	I	ntangible Assets
2023	\$	10,660	\$	4,421
2024		10,660		3,661
2025		10,660		3,658
2026		10,660		3,658
2027		10,660		1,278
Thereafter		24,126		1,852
	\$	77,426	\$	18,528

Contract Liabilities

City of Hope defers recognition of revenue received in advance of certain performance objectives, including fundraising events, research grants, and other agreements prior to such funds being earned. The following is a summary of contract liabilities as of September 30:

	2022		2021	
Fundraising events and other activities Donor-restricted conditional contributions	\$	3,486 \$ 1,032	3,446 749	
Grants revenue		11,008	12,218	
Accelerated and advance payment funds (see Note 18,				
COVID-19 Pandemic)		_	102,404	
Total contract liabilities	\$	15,526 \$	118,817	

For the fiscal years ended September 30, 2022 and 2021, \$15,025 and \$24,053, respectively, was recognized in revenue from contract liabilities.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

Net Assets Without Donor Restrictions

A rollforward of controlling interests and noncontrolling interests net assets without donor restrictions for the fiscal years ended September 30, 2022 and 2021 is as follows:

	Controlling N	oncontrolling	
	Interests	Interests	Total
Delance of Contember 20, 2020	Ф 2.465.429 Ф	20.594 \$	2 406 022
Balance as of September 30, 2020 Excess (deficiency) of revenues, gains, and	\$ 3,465,438 \$	30,584 \$	3,496,022
other support over expenses	560,836	(963)	559,873
Balance as of September 30, 2021	4,026,274	29,621	4,055,895
Deficiency of revenues, gains, and other			
support over expenses	(749,828)	1,118	(748,710)
Distribution to noncontrolling interest		(1,462)	(1,462)
Balance as of September 30, 2022	\$ 3,276,446 \$	29,277 \$	3,305,723

Contributions

All contributions are considered without donor restrictions, unless specifically restricted by the donor. Amounts received that are designated for future periods or are restricted by the donor for specific purposes are reported as contributions with donor restrictions.

Net assets with donor restrictions consist of assets that are subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulated that resources be maintained in perpetuity in a true endowment. All other contributions without donor restrictions are considered net assets without donor restrictions.

Restricted monetary gifts are held in net assets with donor restrictions until the designation is met. When the donor designation is met, a stipulated time restriction ends, or a purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported on the consolidated statements of activities as net assets released from

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

restrictions. Donor-restricted contributions whose restrictions are met within the same fiscal period as the contributions are received are also reflected as net assets released from restrictions on the accompanying consolidated statements of activities.

Contributions

City of Hope is the beneficiary under various wills and trust agreements of which the total realizable amount is not readily determinable at the date of gift. In the case of wills, such amounts are recognized as contributions when the will is declared valid by a probate court and the proceeds are measurable. For the fiscal years ended September 30, 2022 and 2021, valid will and trust agreement amounts that became measurable totaled \$35,391 and \$39,904, respectively, and are included in contributions on the accompanying consolidated statements of activities.

Promises to Give

City of Hope reports unconditional promises to give as contributions with donor restrictions. Unconditional promises to give that are expected to be collected in future years are recorded at the present value of their estimated future cash flows.

The net unconditional promises to give that are greater than one year reported in the accompanying consolidated statements of financial position consist of the following as of September 30:

	 2022	2021
Unconditional promises to give	\$ 217,293 \$	152,995
Less:		
Discounts	(11,424)	(5,967)
Allowance for uncollectible promises to give	(12,560)	(12,541)
Total unconditional promises to give, net	 193,309	134,487
Less current portion	 (48,209)	(38,159)
	\$ 145,100 \$	96,328

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

The discounts on these amounts are computed using risk-free interest rates approximating the U.S. Treasury Note rate when the unconditional promise is made. The rates used in the fiscal years ended September 30, 2022 and 2021 were between 1.11% to 3.64% and 0.34% to 1.11%, respectively. The allowance for uncollectible promises to give was determined based on City of Hope's historical experience with collections. Changes in the allowance for uncollectible promises to give and the amortization of pledge discounts are included in contribution revenue to the extent previously recognized when collected. Subsequent changes in the collectability of promises to give are included in other expense on the accompanying consolidated statements of activities.

As of September 30, 2022, future cash flows anticipated for subsequent fiscal years from unconditional promises to give are as follows:

2023	\$ 48,209
2024	32,801
2025	31,873
2026	24,619
2027	26,982
Thereafter	 52,809
	217,293
Discounts	(11,424)
Allowance for uncollectible promises to give	 (12,560)
	\$ 193,309

City of Hope reports conditional promises to give as contribution revenue when the conditions stipulated by the donor are met, at which time the conditional promise becomes unconditional.

Prior to September 30, 2021, City of Hope received a conditional promise in the amount of \$35,000. There were specific project goals and milestones that must have been met to receive the payments under the agreement. City of Hope recorded \$4,167 in the fiscal year ended September 30, 2021 in contribution revenue, in recognition of attaining specified project goals and milestones. As of September 30, 2021, this conditional promise to give has been fulfilled, because all project goals and milestones have been met and, accordingly, all contribution revenue has been recognized.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

In addition to the conditional promise noted above, City of Hope has received cash payments in advance of meeting other specific project goals and milestones, totaling \$1,032 and \$749 as of September 30, 2022 and 2021, respectively. These amounts are included within contract liabilities on the accompanying consolidated statements of financial position.

Split-Interest Agreements

City of Hope receives contributions from various types of split-interest agreements, including charitable gift annuities, charitable remainder annuity trusts, and charitable remainder unitrusts. City of Hope may be named as a trustee or a co-trustee, or a financial institution may be named as the trustee. Under a charitable gift annuity arrangement, City of Hope recognizes the agreement in the period in which the contract is executed. The assets from the donor are recognized at fair value, and the liabilities designated by the donor to various beneficiaries are recognized at the present value of the estimated future payments to be distributed by City of Hope to such beneficiaries. The difference between the assets and liabilities represents the amount of the contribution revenue.

Some states have laws that mandate certain requirements regarding gift annuity reserves. These laws can be based on where the nonprofit entity is located or where the gift annuity donor resides. City of Hope has state-mandated reserves above the actuarial annuity reserves in the amount of \$626 and \$682 as of September 30, 2022 and 2021, respectively. Additionally, City of Hope has voluntary reserves in the amount of \$5,188 and \$9,821 as of September 30, 2022 and 2021, respectively, that are to protect the reserve fund against unexpected market fluctuations and actuarial changes. These voluntary reserves are included in investments and net assets without donor restrictions on the accompanying consolidated statements of financial position.

Under charitable trust arrangements in which City of Hope is not the trustee or is a co-trustee, City of Hope recognizes, in the period the agreement is executed, donor-restricted long-term contribution receivables and contribution revenues at the present value of the estimated future benefits to be received when the trust assets are expected to be distributed. Trust distributions are recorded as a reduction in receivables, while adjustments to the receivables to reflect amortization of the discount and changes in actuarial assumptions during the term of the trust are recorded as donor-restricted contributions on the accompanying consolidated statements of activities. Receivables totaling \$106,867 as of September 30, 2022 are to be collected over the next 45 years and have an average remaining life of 15.1 years. For the fiscal year ended September 30, 2021,

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

\$95,014 was recognized as contribution revenue related to split-interest agreements. There was no contribution revenue related to split-interest agreement recognized for the fiscal year ended September 30, 2022.

Research Grants, Contracts, and Clinical Trials Revenue

Research grants, contracts, and clinical trials revenue includes federal, state, and local jurisdiction awards and other exchange transactions. An exchange transaction is one in which there is reciprocal benefit where each party receives approximate commensurate value. Research grants, contracts, and clinical trials revenue is recognized in the period it is earned based on when the applicable project expenses have been incurred and project milestones are achieved. Payments received in advance of related project expenses are recorded in contract liabilities on the accompanying consolidated statements of financial position.

Royalty and Licensing Revenue

City of Hope receives revenues from various licensing and royalty agreements. During the fiscal years ended September 30, 2022 and 2021, City of Hope recognized licensing and royalty revenue totaling \$19,916 and \$114,247, respectively. In 2021, the licensing revenue was primarily from TGen's proprietary TARDIS blood biopsy technology. No additional revenue was received for TARDIS for the fiscal year ended September 30, 2022. In addition, royalties were generated from sales of drugs from Genentech using technology developed at the Institute and covered by the Cabilly patents.

On January 11, 2021, TGen and Exact Sciences Corporation ("Exact Sciences") entered into a worldwide exclusive license to TGen's rights in its proprietary TARDIS blood biopsy technology. TARDIS was developed to be highly sensitive and customizable for each patient to detect trace amounts of tumor DNA in a patient's blood after his or her initial treatment. Exact Sciences acquired the license for an up-front cash payment of \$25,000 and 191,336 shares of Exact Science's common stock valued at \$25,073 on the date of issuance. Accordingly, TGen recorded \$50,073 of licensing revenue for the fiscal year ended September 30, 2021. Under the terms of the license, Exact Sciences is required to pay cash of \$10,000 and \$35,000 upon achieving cumulative product revenue milestones of \$100,000 and \$250,000, respectively. These payments are contingent upon achievement of these cumulative revenues on or before December 31, 2030. As of September 30, 2022, no milestones have been achieved and, therefore, no milestone revenue has been recorded.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

The Cabilly patents expired during the first quarter of fiscal year 2019, with some royalty revenue anticipated to continue beyond the fiscal year ended September 30, 2022. City of Hope recognizes estimated royalty revenue in the same period the sales occur, in accordance with ASU 2014-09, Revenue from Contracts with Customers ("Topic 606"). Accordingly, City of Hope's royalty revenue and royalty sharing expense are reported on an accrual basis to match the period of related sales that generates the royalties.

Royalty and Licensing Revenue

City of Hope has entered into various licensing agreements, whereby equity interests in the licensee are received as compensation. The stock and membership units related to these agreements are recorded at fair value.

Income Taxes

City of Hope is exempt from federal income tax under Section 501(c)(3) of the U.S. Internal Revenue Code. City of Hope, the Center, the Foundation and the Institute are exempt from California state franchise and income tax under Section 23701(d) of the California Revenue and Taxation Code.

TGen is exempt from Arizona corporate income tax under Section 43-1201(A) of the Arizona Revised Statutes. The 100% wholly owned entities of TGen are single-member, limited liability companies and are considered disregarded entities for tax purposes.

AH is majority owned by City of Hope and is treated as a partnership for federal and state income tax purposes. All taxable income is allocated to the partners in accordance with the respective partnership agreement.

SCRO is treated as a partnership for federal and state income tax purposes, where all taxable income is allocated to the partners in accordance with the respective partnership agreement; accordingly, federal and state taxes on income are the responsibility of the joint partners individually.

As of September 30, 2022, Holdco is exempt from Federal income tax under Section 501(c)(3) of the U.S. Internal Revenue Code. Prior to Holdco's conversion to a tax exempt organization, the entity was treated as a C-corporation for federal and state income tax purposes.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

2. Summary of Significant Accounting Policies (continued)

ASC 740, *Income Taxes*, clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. ASC 740 also provides guidance on de-recognition, measurement, classification, interest and penalties, disclosure, and transition. The guidance contained in ASC 740 is applicable to pass-through entities and tax-exempt organizations. City of Hope has no significant uncertain tax positions or tax liability for tax benefits, interest, or penalties accrued as of September 30, 2022 or 2021.

Derivative and Hedging Instruments

City of Hope recognizes all derivatives at fair value on the consolidated statements of financial position. The derivative instruments include interest swaps and treasury rate locks (see Note 4, Fair Value of Financial Instruments).

3. Business Combinations

Acquisition of the CTCA Entities

On February 1, 2022, HoldCo, a nonprofit Delaware corporation of which City of Hope is the sole corporate member, acquired 100% of the outstanding shares and voting interest of the CTCA Entities. The CTCA Entities are a network of cancer treatment facilities in the Atlanta, Chicago, and Phoenix metropolitan areas. The primary reason for the business combination was to expand access to world-class research and cancer care to patients nationally.

City of Hope accounted for the transaction as a business combination in accordance with ASC 958-805, *Not-for-Profit Entities: Business Combinations*, and recorded the assets acquired and liabilities assumed at fair value. The amount, if any, by which the purchase price exceeded the fair value of the net assets acquired was recorded as goodwill. City of Hope utilized market-based and cost-based valuation approaches to perform the purchase price allocation.

Notes to Consolidated Financial Statements (continued)

(Dollar Amounts Expressed in Thousands)

3. Business Combinations (continued)

No goodwill was recognized for the acquisition of the CTCA Entities, as the aggregate of consideration transferred equaled the acquisition date fair value of the net identifiable assets acquired:

Total cash consideration transferred	\$ 364,372
Net identifiable assets acquired at fair value	364,372

The following table summarizes the acquisition date fair value of the assets acquired and liabilities assumed using Level 3 inputs (refer to Note 4, Fair Value of Financial Instruments), which City of Hope recognized upon completing the transaction:

Identifiable assets:	
Cash and cash equivalents	\$ 20,402
Patient account receivable	120,218
Due from affiliates	473
Due from third-party payors	1,657
Grants and other receivables	9,807
Inventory	18,827
Prepaid and other	24,138
Property and equipment	320,787
Right-of-use operating lease assets	7,246
Intangible assets	15,600
Other long-term assets	90
Total identifiable assets	 539,245
Liabilities assumed:	
Accounts payable and other accrued liabilities	89,738
Accrued salaries, wages, employee benefits	15,917
Contract liabilities	22,450
Due to affiliates	813
Due to related parties	2,731
Right-of-use operating leases, current portion	3,264
Due to third-party payors	32,892
Right-of-use operating leases, net of current portion	3,982
Other long-term liabilities	3,086
Total liabilities assumed	 174,873
Net identifiable assets	\$ 364,372

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

3. Business Combinations (continued)

The intangible asset acquired in connection with the acquisition represents the tradename. The weighted-average amortization period for the acquired tradename was five years.

The following summarizes the financial results of the CTCA Entities included in the accompanying consolidated financial statements from the date of the acquisition through September 30, 2022:

Revenues, gains and other support	\$ 537,121
Changes in net assets without donor restrictions	(96,763)
Changes in net assets with donor restrictions	_

Supplemental Unaudited Pro Forma Information

The unaudited pro forma information presented below is for illustrative purposes only and does not purport to be indicative of the results of future operations or the results that would have occurred had City of Hope completed the acquisition on October 1, 2020.

The unaudited pro forma results for the years ended September 30, 2022 and 2021 include the historical results of the CTCA Entities for the four-month period ended January 31, 2022 and for the year ended September 30, 2021 prior to the acquisition, respectively. The unaudited pro forma results include pro forma adjustments related to nonrecurring transaction and integration costs, depreciation on acquired property and equipment, amortization of intangible assets at the date of the acquisition, accounting policy alignment for ASC 842, *Leases*, and interest expense associated with financing the transaction, as though the acquisition was completed on October 1, 2020. Below presents the unaudited pro forma results for the fiscal years ended September 30:

	2022			2021				
		Actual	Pr	o Forma (a)		Actual	Pr	o Forma (a)
Revenues, gains, and other support	\$	3,064,597	\$	3,334,917	\$	3,337,975	\$	4,169,033
Expenses		3,768,470		3,998,275		2,550,297		3,579,044
Changes in net assets without donor restrictions		(750,172)		(709,656)		559,873		362,184
Changes in net assets with donor restrictions		44,837		44,837		227,805		227,805

⁽a) Includes a pro forma adjustment for transaction and integration costs of approximately \$80,000 incurred during the fiscal year ended September 30, 2022, which is primarily related to advisory professional services provided by third parties. The pro forma adjustment moves the transaction and integration costs from fiscal year 2022 to fiscal year 2021, as though the acquisition had occurred as of the beginning of fiscal year 2021.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

3. Business Combinations (continued)

Acquisition of the Practice

Effective August 6, 2021, the Foundation entered into an Asset Purchase Agreement ("APA") with a medical practice group headquartered in Southern California (the "Practice") for substantially all the assets of the Practice as further defined in the APA. This acquisition added multiple practice locations to City of Hope, expanding City of Hope's presence in Southern California. The business combination was recorded under the acquisition method of accounting and applied related accounting guidance as required in accordance with ASC 958-805.

The table below presents the consideration paid for the Practice and the acquisition date fair value of the net identifiable assets acquired:

Cash consideration transferred	\$ 57,102
NI . 11 . 10 11	
Net identifiable assets:	
Inventory	\$ 6,813
Property and equipment	1,088
Other assets	45
Noncompete agreement	188
Tradename	1,436
Goodwill	 47,532
Total net identifiable assets	\$ 57,102

The weighted average amortization period upon acquisition for the noncompete agreement, tradename and goodwill was two years, two years, and ten years, respectively. Goodwill represents the excess of the purchase price over the fair value of the net identifiable assets acquired and liabilities assumed. Goodwill primarily represents, among other factors, the value of synergies expected to be realized and the assembly of workforce that enables City of Hope to increase treatment options, neither of which qualify as separate amortizable intangible assets. Intangible assets are recorded at estimated fair value, as determined by management based on available information. Management applied significant judgment in determining the fair value of intangible assets, which involved the use of estimates and assumptions including future revenue and related operating profits, and other projected financial information.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

4. Fair Value of Financial Instruments

The consolidated statements of financial position include the following financial instruments: cash and cash equivalents, patient accounts receivable, grants and other receivables, short- and long-term investments, prepaid and other, accounts payable and other accrued liabilities, estimated amounts due to third-party payors, interest rate swaps and treasury rate locks, and annuity and split-interest agreement obligations. City of Hope considers the carrying amounts of current assets and liabilities (except for investment securities, which are carried at fair value, as described in Note 2) on the consolidated statements of financial position to approximate the fair value of these financial instruments because of the relatively short period of time between origination of the instruments and their expected realization.

As defined by ASC 820, *Fair Value Measurement*, fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements, a fair value hierarchy was established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below.

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets but can be corroborated by market data.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Assets and liabilities measured at fair value are based on one or more of three valuation techniques as identified in the tables below. Where more than one technique is noted, individual assets or liabilities were valued using one or more of the noted techniques. The valuation techniques are as follows:

- (a) *Market approach*. Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.
- (b) *Cost approach*. Amount that would be required to replace the service capacity of an asset (replacement cost).

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

4. Fair Value of Financial Instruments (continued)

(c) *Income approach*. Techniques to convert future amounts to a single present amount based on market expectations (including present value techniques, option-pricing, and excess earnings models).

In determining fair value, City of Hope utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk, in its assessment of fair value. The fair value of annuity and split-interest obligations has been determined using present value techniques based on mortality tables and discount rates that are consistent with Internal Revenue Service published rates and the American Council on Gift Annuities.

City of Hope uses interest rate swaps to manage interest rate risk associated with the floating-rate debt. City of Hope entered into treasury rate locks within the fiscal year September 30, 2022, as part of its investment strategy. The valuation of these instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period of maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of treasury rate locks are determined using comparable market transactions. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. City of Hope incorporates credit valuation adjustments to appropriately reflect both its own nonperformance risk and the respective counterparty's nonperformance risk in the fair value measurements.

City of Hope's assets and liabilities, measured at fair value on a recurring basis or at net asset value, as of September 30, aggregated by the level in the fair value hierarchy, are as follows:

Notes to Consolidated Financial Statements (continued)

(Dollar Amounts Expressed in Thousands)

4. Fair Value of Financial Instruments (continued)

			I	nvestments	at	Fair Value			I	nvestments at Net			Valuation Technique
2022		Level 1		Level 2		Level 3]	Fair Value		Asset Value		Total	(a, b, c)
Investments													• • • • • • • • • • • • • • • • • • • •
U.S. Government and agency													
obligations	\$	_	\$	11,266	\$	_	\$	11,266	\$	_	\$	11,266	a, b
Corporate obligations		_		510		_		510		_		510	a, b
Marketable securities		918,277		_		_		918,277		_		918,277	a
Public real assets		11		-		_		11		_		11	a
Municipal obligations		_		886		_		886		_		886	a
Preferred stock		_		_		612		612		_		612	c
Hedge funds		_		_		_		_		409,733		409,733	
Equity commingled funds		_		_		_		_		974,710		974,710	
Private equity funds		_		_		_		_		592,900		592,900	
Private real assets		_		_		_		_		260,205		260,205	
Certificates of deposit		_		32,000		_		32,000		_		32,000	a, b
Cash equivalents		212,491		_		_		212,491		_		212,491	a
Treasury rate locks		_		49,418		_		49,418		_		49,418	a
Total investments	\$	1,130,779	\$	94,080	\$	612	\$	1,225,471	\$	2,237,548	\$	3,463,019	Ī
Prepaid and other current assets													
Interest rate swaps	\$	_	\$	8,579	\$	_	\$	8,579	\$	_	\$	8,579	
merest face swaps	Ψ		Ψ	0,577	Ψ		Ψ	0,577	Ψ		Ψ	0,577	:
Other long-term assets													
Marketable securities	\$	44,441	\$	_	\$	_	\$	44,441	\$	_	\$	44,441	a
Cash equivalents	\$	539	\$	_	\$	_	\$	539	\$	_	\$	539	a
Interest rate swaps	\$	-	\$	8,574	\$	-	\$	8,574	\$	-	\$	8,574	
Total investments, prepaid and other current assets, and other													•
long-term assets	\$	1,175,759	\$	111,233	\$	612	\$	1,287,604	\$	2,237,548	\$	3,525,152	:
						Level 1		Level 2		Level 3		Total	
Liabilities at fair value													
Annuity and split-interest													
obligations					\$	-	\$	-	\$	27,854	\$	27,854	c
Interest rate swaps						_		2,232				2,232	a, b
Total liabilities					\$	_	\$	2,232	\$	27,854	\$	30,086	<u>.</u>

Notes to Consolidated Financial Statements (continued)

(Dollar Amounts Expressed in Thousands)

4. Fair Value of Financial Instruments (continued)

	_		I	nvestments	at !	Fair Value			_ I	nvestments at Net			Valuation Technique
2021		Level 1		Level 2		Level 3]	Fair Value	A	sset Value		Total	(a, b, c)
Investments													
U.S. Government and agency													
obligations	\$	_	\$	60,816	\$	_	\$	60,816	\$	_	\$	60,816	a, b
Corporate obligations		-		243,730		_		243,730		_		243,730	a, b
Asset-backed obligations		_		122,766		_		122,766		_		122,766	a, b
Mortgage-backed obligations		_		115,377		_		115,377		_		115,377	a, b
Marketable securities		1,201,633		-		_		1,201,633		_		1,201,633	a
Public real assets		14		-		_		14		_		14	a
Municipal obligations		_		1,220		_		1,220		_		1,220	a
Preferred stock		_		_		612		612		_		612	c
Hedge funds		_		-		_		_		376,865		376,865	
Equity commingled funds		_		-		_		_		1,187,670		1,187,670	
Private equity funds		_		-		_		_		523,866		523,866	
Private real assets		_		-		_		_		222,278		222,278	
Certificates of deposit		_		182,000		_		182,000		_		182,000	a, b
Cash equivalents	_	143,161			_		_	143,161	_		_	143,161	a
Total investments	\$	1,344,808	\$	725,909	\$	612	\$	2,071,329	\$	2,310,679	\$	4,382,008	
Other long-term assets													
Marketable securities	\$	46,938	\$	_	\$	_	\$	46,938	\$	_	\$	46,938	a
Cash equivalents	\$	551	\$		\$		\$	551	\$		\$	551	a
Total investments and other	Ψ	331	Ψ		Ψ		Ψ	331	Ψ		Ψ	331	ű
long-term assets	\$	1,392,297	\$	725,909	\$	612	\$	2,118,818	\$	2,310,679	\$	4,429,497	
	_												
						Level 1		Level 2		Level 3		Total	
Liabilities at fair value Annuity and split-interest													
obligations					\$	_	\$	_	\$	27,707	\$	27,707	c
Interest rate swaps						_		19,497		_		19,497	a, b
Total liabilities					\$	_	\$	19,497	\$	27,707	\$	47,204	•

Other long-term assets consist of 457(b) plans that are funded by plan participants of City of Hope.

Notes to Consolidated Financial Statements (continued)

(Dollar Amounts Expressed in Thousands)

4. Fair Value of Financial Instruments (continued)

The table below sets forth a summary of changes in fair value of the Level 3 assets and liabilities for the fiscal years ended September 30, 2022 and 2021:

	 Assets	L	iabilities
Beginning balance as of September 30, 2020	\$ 612	\$	19,849
Additions	_		6,211
Investment activity	_		280
Distributions	_		(1,294)
Change in fair value	 _		2,661
Beginning balance as of September 30, 2021	612		27,707
Additions	_		3,875
Investment activity	_		359
Distributions	_		(1,516)
Change in fair value	 _		(2,571)
Ending balance as of September 30, 2022	\$ 612	\$	27,854

As of September 30, 2022, City of Hope has certain equity investments where it does not have significant influence. In accordance with ASC 321, *Investments – Equity Securities*, City of Hope has elected to measure at cost minus impairment as the investments in privately held companies did not have a readily determinable fair values given no observable transactions, and no impairment was recorded as of September 30, 2022.

Notes to Consolidated Financial Statements (continued)

(Dollar Amounts Expressed in Thousands)

4. Fair Value of Financial Instruments (continued)

The following reconciles fair value amounts to the consolidated statements of financial position as of September 30:

	2022	2021
Cash and cash equivalents	\$ 232,284	\$ 262,033
Investments, current	1,555,739	2,166,955
Self-insurance trust funds	3,959	3,608
Investments held for long-term purposes	18,892	38,750
Board-designated assets	1,050,182	1,229,844
Bond trust funds	160,785	245,730
Donor-restricted investments	667,392	682,583
	3,689,233	4,629,503
Less investment at net asset value	(2,237,548)	(2,310,679)
Less amounts held in operating cash	(226,214)	(247,495)
Plus amounts in other long-term assets	53,554	47,489
Plus amounts in prepaid and other	8,579	_
Investments at fair value	\$ 1,287,604	\$ 2,118,818

5. Patient Accounts Receivable and Patient Service Revenues

The following table summarizes the percentages of gross accounts receivable from patients and third-party payors as of September 30:

2022	2021
23%	21%
4	6
68	70
5	3
100%	100%
	23% 4 68 5

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

5. Patient Accounts Receivable and Patient Services Revenues (continued)

Net patient service revenues for the fiscal years ended September 30 are as follows:

	2022		2021
Medicare	\$	737,279	\$ 496,406
Medicaid		191,915	135,134
Contracted plans (including commercial,			
Medicare Advantage, and Medicaid managed care)		1,925,593	1,206,636
Indemnity, self-pay, and other		70,666	13,199
Patient service revenues	\$	2,925,453	\$ 1,851,375

6. Patient Charity Care

The Center, the Foundation, and the CTCA Entities provide care to patients who do not have the ability to pay and who qualify for charity care pursuant to established policies of the Center, the Foundation and the CTCA Entities. Charity care is defined as services for which patients have the obligation to pay but do not have the ability to do so. Certain medically necessary services provided to Medicaid patients who are not reimbursed by the Medicaid program have been included in the estimated cost of patient charity care. The Center, the Foundation and the CTCA Entities do not report charity care as net patient service revenue. The estimated cost for both patient charity care and Medicaid patients represents the total direct and indirect cost calculated at the medical procedure level and pertains specifically to the respective charity and Medicaid patient populations. Procedure-level cost includes the direct costs, such as labor and supplies, involved in providing the specific service, as well as an applicable allocation of departmental overhead (e.g., departmental management) and institutional overhead (e.g., administration, depreciation, and utilities).

The cost of charity care provided during the fiscal years ended September 30, 2022 and 2021 was \$25,726 and \$18,486, respectively. For the fiscal year ended September 30, 2022, \$6,313 related to the CTCA Entities. See Note 17, Community Benefit Expense (Unaudited), for additional disclosure related to benefits for the broader community and support of governmental health care programs (excluding the CTCA Entities).

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

7. Property and Equipment, Net

A summary of the cost and accumulated depreciation and amortization of property and equipment as of September 30 is as follows:

	2022	2021
Land	\$ 90,555	\$ 54,512
Buildings	1,334,745	858,741
Leasehold improvements	209,656	65,451
Equipment and furniture	911,389	706,927
Software	384,515	304,414
	2,930,860	1,990,045
Accumulated depreciation and amortization	(1,329,777)	(1,159,684)
	1,601,083	830,361
Construction-in-progress	451,640	581,930
Total property and equipment, net	\$ 2,052,723	\$ 1,412,291

Depreciation and amortization expense on property and equipment totaled \$172,812 and \$138,595 for the fiscal years ended September 30, 2022 and 2021, respectively.

8. Liquidity and Availability

City of Hope's financial assets available for general expenditure within one year of September 30 include the following:

	2022	2021
Cash and cash equivalents	\$ 232,284	\$ 262,033
Investments	1,555,739	2,166,955
Patient accounts receivable	464,078	319,133
Grants and other receivables	174,032	156,100
Board-designated assets	1,050,182	1,229,844
	\$ 3,476,315	\$ 4,134,065

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

8. Liquidity and Availability (continued)

As part of City of Hope's liquidity management plan, cash in excess of any daily requirement is invested in long-term investments. The long-term investment portfolio contains liquid investments that can be drawn upon if necessary to meet liquidity needs.

Board-designated assets include funds set aside to function as institutionally designated endowments as established by the Board of Directors for future research, program services, and capital expenditures for City of Hope. Board-designated assets can be used for liquidity purposes related to research, program services, and capital expenditures upon the approval of the Board of Directors.

City of Hope invests in alternative investments to increase the investment portfolio's diversification. The nature of alternative investments generally restricts the liquidity and availability of these investments to be available for the general expenditures of City of Hope within one year of the consolidated statements of financial position. These investments and those assets limited as to use included in self-insurance trust funds, investments held for long-term purposes, bond trust funds, and donor-restricted funds have not been included in the amounts above.

Line of Credit

On April 21, 2020, City of Hope entered into a syndicated unsecured revolving line of credit (the "April 2020 Line of Credit") with two banking institutions for a combined amount of \$450,000, which expired on April 20, 2021. Prior to the expiration, City of Hope borrowed \$450,000. City of Hope repaid the outstanding balance of \$450,000 on February 24, 2021 and amended this agreement with three banking institutions on April 21, 2021 to extend the line of credit to April 20, 2022. Prior to expiration, City of Hope extended its syndicated unsecured revolving line of credit with four banking institutions with an additional term of three years (April 2025). As of September 30, 2022, City of Hope has not drawn on this line of credit. An unutilized fee of 0.275% or \$838, was assessed during the fiscal year ended September 30, 2022.

Standby Letter of Credit

City of Hope maintains standby letters of credit as required by various agencies to which City of Hope is a party. To secure its obligation under a long-term right-of-use finance lease agreement, TGen purchased an irrevocable standby letter of credit in the amount of up to \$25,000 for the benefit of the lessor. The standby letter of credit automatically reduces, without amendment, on various dates.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

8. Liquidity and Availability (continued)

As of September 30, 2022, the available amount on the standby letter of credit is \$15,000. The standby letter of credit is guaranteed by City of Hope and will renew annually based on a preagreed amortization schedule, unless terminated with a 60-day notice prior to the annual anniversary date by the lender. This letter of credit expires no later than October 1, 2035. As of September 30, 2022, no amounts are outstanding on the standby letters of credit.

9. Long-Term Debt

The following is a summary of City of Hope's long-term debt as of September 30:

	2022	2021
City of Hope, 3.750% to 5.000% fixed rate Tax-Exempt Revenue Bonds Series 2012A, originally \$234,635, issued through the California Health Facilities Financing Authority, with varying maturities annually through November 15, 2039. Interest payable semiannually on May 15 and November 15 (Series 2012A Revenue Bonds)	\$ 187,795	\$ 194,635
City of Hope, 5.623% fixed rate Taxable Direct Obligation Notes, originally \$350,000. Interest payable semiannually on May 15 and November 15, principal payment due in full on November 15, 2043 (Series 2013 Notes)	350,000	350,000
City of Hope, Tax-Exempt variable rate Revenue Notes Series 2017A, originally \$32,680, issued through the California Health Facilities Financing Authority. Interest payable monthly, principal payments annually beginning on November 15, 2039 through November 15, 2042 (Series 2017A Revenue Notes)	32,680	32,680
(======================================	,000	2=,000

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

9. Long-Term Debt (continued)

	 2022	2021
City of Hope, Tax-Exempt variable rate Revenue Notes Series 2017B, originally \$32,680, issued through the California Health Facilities Financing Authority. Interest payable monthly, principal payments annually beginning on November 15, 2039 through November 15, 2042 (Series 2017B Revenue Notes)	\$ 32,680 \$	32,680
City of Hope, 4.378% fixed rate Taxable Direct Obligation Notes, originally \$300,000. Interest payable semiannually on February 15 and August 15, principal payment due in full on August 15, 2048 (Series 2018 Notes)	300,000	300,000
City of Hope, 4.000%–5.000% fixed rate Tax-Exempt Revenue Bonds Series 2019, originally \$334,905, issued through the California Health Facilities Financing Authority. Interest payable semiannually on May 15 and November 15, principal payments annually beginning on November 15, 2024, through November 15, 2049 (Series 2019 Revenue Bonds)	334,905	334,905
TGen, 1.690%–4.220% fixed rate notes. Principal and interest due monthly or annually through April 2022 (TGen Notes)	7,000	7,100
Bridge Loan, variable rate interest due monthly and principal due on January 30, 2023	649,590	
	1,894,650	1,252,000
Less current maturities of long-term debt	(7,190)	(6,940)
Less unamortized bond issue costs	(3,513)	(3,696)
Less unamortized discount	(6,007)	(6,307)
Plus unamortized premium	 56,906	60,329
	\$ 1,934,846 \$	1,295,386

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

9. Long-Term Debt (continued)

Long-term debt maturities as of September 30, 2022, and payments for subsequent fiscal years are as follows:

2023	\$ 7,190
2024	664,150
2025	7,950
2026	10,870
2027	11,430
Thereafter	1,193,060_
	\$ 1,894,650

Series 2012 Revenue Bonds (Tax-Exempt) – In November 2012, City of Hope, as representative of the Obligated Group, issued \$234,635 of Tax-Exempt Series 2012A fixed rate Revenue Bonds, \$32,500 of Tax-Exempt Series 2012B Variable Rate Revenue Bonds, and \$32,500 of Tax-Exempt Series 2012C Variable Rate Revenue Bonds through the California Health Facilities Financing Authority. The Series 2012A Revenue Bonds were issued at a premium totaling \$29,887. The Series 2012 Revenue Bonds are secured by a gross receivables pledge. The Series 2012B and Series 2012C Bonds were subsequently refunded by the Series 2017 Bonds as further described below.

Series 2013 Notes (Taxable) – In July 2013, City of Hope, as representative of the Obligated Group, issued \$350,000 of Series 2013 fixed rate Direct Obligation Notes. The proceeds from the Series 2013 Notes are used for the Obligated Group's capital needs in furtherance of the implementation of the Obligated Group's strategic plan. The Series 2013 Notes are secured by a gross receivables pledge.

Series 2017 Revenue Notes (Tax-Exempt) – In February 2017, City of Hope, as representative of the Obligated Group, refunded the Series 2012B Variable Rate Revenue Bonds in the amount of \$32,500 and the Series 2012C Variable Rate Revenue Bonds in the amount of \$32,500 with two new issues through the California Health Facilities Financing Authority, Variable Rate Revenue Notes Series 2017A Variable Rate Revenue Notes in the amount of \$32,680 and Series 2017B Variable Rate Revenue Notes in the amount of \$32,680 and Series 2017B Variable Rate Revenue Notes in the amount of \$32,680. The Series 2017 Revenue Notes were directly purchased by a commercial bank and have the same maturity and approximate principal amortization as the refunded Series 2012B and Series 2012C Revenue Bonds and bear interest based on 70% of the one-month London Interbank Offered Rate (LIBOR) plus a spread. The Series 2017 Revenue Notes are secured by a gross receivables pledge.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

9. Long-Term Debt (continued)

Series 2018 Notes (Taxable) – In May 2018, City of Hope, as representative of the Obligated Group, issued \$300,000 of Series 2018 Notes. The proceeds from the Series 2018 Notes are used for the Obligated Group's capital needs in furtherance of the implementation of the Obligated Group's strategic plan, including geographic expansion, addressing patient capacity, informatics, developing precision medicine, and funding research to support the development of innovative treatments. The Series 2018 Notes are secured by a gross receivables pledge.

Series 2019 Revenue Bonds (Tax-Exempt) – In July 2019, City of Hope, as representative of the Obligated Group, issued \$334,905 of Series 2019 Revenue Bonds through the California Health Facilities Financing Authority. The proceeds from the Series 2019 Revenue Bonds are being used for the construction and equipping of an outpatient clinic; a parking structure to support the outpatient clinic and balance parking requirements across the campus; and the construction of a building that will provide accommodations for patients, family members, and guests. The Series 2019 Revenue Bonds were issued at a premium totaling \$49,624 and are secured by a gross receivables pledge.

Bridge Loan – On January 31, 2022, HoldCo entered into a \$650,000 bridge loan (the "Bridge Loan"): (1) to finance the purchase of the CTCA Entities; (2) to provide working capital; and (3) for general corporate purposes. The Bridge Loan matures on January 30, 2023 (see Note 20, Subsequent Events, regarding issuance of bonds to pay off the Bridge Loan). The Bridge Loan is guaranteed by the Obligated Group and is secured by an obligation issued under the Obligated Group's Master Trust Indenture

Interest Rate Swap Transactions – The Obligated Group entered into two interest rate swap agreements, with a notional amount of \$65,000, to synthetically convert the Series 2012B and Series 2012C Revenue Bonds from a variable rate to a fixed rate of 2.715% and 2.720%, respectively. The Obligated Group receives a floating rate equal to 70% of the USD-LIBOR-BBA. The Series 2012B and Series 2012C Revenue Bonds were subsequently refunded by Series 2017 Revenue Notes; however, the related swap transactions remain in place as a hedge against the variable interest rate payments on the 2017 Bonds.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

9. Long-Term Debt (continued)

In February 2020, City of Hope entered into two forward-starting interest rate swap agreements with each having a notional amount of \$71,355 (total \$142,710) that became effective on November 15, 2022. These swaps were entered into in anticipation of a current refunding of a portion the Series 2012A Bonds. The Obligated Group will receive a variable rate of 70% of the Federal Funds rate and will pay a fixed rate of 0.8785% and 0.8805%, respectively, to its swap counterparties. On the effective date, the swap transactions are expected to produce positive cashflow payments to City of Hope. One of the swap agreements was subsequently terminated on its effective date (see Note 20, Subsequent Events).

For the fiscal years ended September 30, 2022 and 2021, the change in the fair value of the interest rate swaps resulted in an unrealized gain of \$34,416 and \$10,882, respectively (see Note 4, Fair Value of Financial Instruments). The swaps were included within long-term liability, prepaid and other, and other long term assets on the accompanying consolidated statements of financial position and were not designated as cash flow hedges, so the changes in fair value are recorded within interest expense on the accompanying consolidated statements of activities. The effect of the counterparty payments and receipts on interest expense for the swaps was an increase of \$1,405 and \$1,713 for the fiscal years ended September 30, 2022 and 2021, respectively.

Financial Covenants – Under the Series 2012 Revenue Bonds, the Series 2013 Notes, the Series 2017 Revenue Notes, the Series 2018 Notes, and the Series 2019 Revenue Bonds, the Obligated Group was in compliance with its financial covenants as of September 30, 2022.

TGen was in compliance with its financial covenants related to its TGen Notes and its right-of-use finance lease liability as of September 30, 2022.

10. Endowment

City of Hope's endowment consists of 132 individual funds established for a variety of purposes. The endowments include both donor-restricted "true" endowment funds, which are classified as net assets with donor restrictions, and funds designated by the Board of Directors to function as an endowment, which are classified as net assets without donor restrictions. City of Hope's endowment is invested in an investment pool.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

10. Endowment (continued)

Interpretation of Relevant Law

ASC 958 provides guidance on the net asset classification of donor-restricted endowment funds for a not-for-profit organization that is subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act of 2006 ("UPMIFA"). City of Hope classifies donor-restricted true endowment funds to include: (1) the original value of gifts donated to the permanent endowment; (2) the original value of subsequent gifts to the permanent endowment; and (3) changes to the permanent endowment made in accordance with the direction of the applicable donor gift instrument. Also included in net assets with donor restrictions is the accumulated appreciation on donor restricted true endowment funds, which are available for expenditure in a manner consistent with the standard of prudence prescribed by UPMIFA, and any deficiencies associated with investments where the value of the fund has fallen below the original value of the gift.

In accordance with UPMIFA, City of Hope considers the following factors when appropriating or accumulating donor-restricted endowment funds:

- The duration and preservation of the fund
- The purposes of the donor-restricted endowment fund
- General economic conditions
- The possible effects of inflation and deflation
- The expected total return from income and appreciation of investments
- Other resources of City of Hope
- The investment policies of City of Hope

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

10. Endowment (continued)

Funds With Deficiencies

From time to time, the fair value of assets associated with individual donor-restricted true endowment funds may fall below the level that the donor or UPMIFA requires to be retained as a fund of perpetual duration. Deficiencies of this nature are reported in donor-restricted true endowment net assets. As of September 30, 2022, twelve funds were deficient with an original gift value of \$14,822 that were deficient by \$1,436. As of September 30, 2021, no funds were deficient.

Return Objectives and Risk Parameters

City of Hope's financial objective is to achieve a long-term rate of return that will enhance and preserve the real inflation-adjusted purchasing power of the corpus without subjecting the investment portfolio to large investment losses. Assets are invested in a manner that is intended to produce results that exceed the respective benchmark while assuming a moderate level of investment risk. Actual returns in any given year may vary from this amount.

Strategies and Endowment Payout

City of Hope relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). City of Hope targets a diversified asset allocation to achieve its long-term return objections within prudent risk constraints. In accordance with City of Hope's total return objective, up to 5% of the annual fair value as measured on January 1 each year is available for expenditure in the form of endowment payout for expenditures or purposes as defined by the endowment agreements.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

10. Endowment (continued)

Strategies and Endowment Payout

Changes in the fair value of City of Hope's endowment investments and other endowment net assets by type of fund for the fiscal years ended September 30, 2022 and 2021 are as follows:

	Without		
	Donor	With Donor	
	Restrictions	Restrictions	Total
Endowment net assets, September 30, 2020	\$ 957,138	\$ 279,360 \$	5 1,236,498
Investment income	8,548	2,838	11,386
Net appreciation	264,688	75,769	340,457
Change in donor designation	_	(10,000)	(10,000)
Contributions	_	6,798	6,798
Appropriation for expenditures	(530)	(7,754)	(8,284)
Endowment net assets, September 30, 2021	1,229,844	347,011	1,576,855
Investment income	11,895	3,712	15,607
Net depreciation	(190,987)	(43,543)	(234,530)
Change in donor designation	_	6,493	6,493
Contributions	_	35,659	35,659
Appropriation for expenditures	(570)	(9,195)	(9,765)
Endowment net assets, September 30, 2022	\$ 1,050,182	\$ 340,137 \$	5 1,390,319

11. Net Assets With Donor Restrictions

Net assets with donor restrictions are available to fund the following purposes as of September 30:

	 2022	2021
Time restricted under annuity and split-interest		
obligations and other	\$ 323,022	\$ 263,378
Patient care	46,542	50,079
Education	32,341	36,975
Research	538,552	548,659
Medical equipment and buildings	17,185	13,714
Total net assets with donor restrictions	\$ 957,642	\$ 912,805

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

11. Net Assets With Donor Restrictions (continued)

Net assets were released from donor restrictions by satisfying the following restricted purposes in the fiscal years ended September 30:

	2022		2021
Time restricted under annuity and split-interest	·		
obligations and other	\$	9,923 \$	15,915
Patient care		3,168	4,190
Education		1,930	2,849
Research		83,461	85,805
Equipment and buildings		355	2,691
Total donor-restricted net assets released			
from restrictions	\$	98,837 \$	111,450

12. Retirement Plans

City of Hope, the Center, the Foundation, AH, and the Institute participate in the City of Hope Defined Contribution Plan (the "Plan"). The Plan was established in 1989 to provide benefits to eligible employees as defined in the plan document and covers substantially all employees. Contributions range between 2% and 10%, depending on years of service and salary, and are calculated on an employee's biweekly base salary up to and above the annual Social Security Taxable wage base, not to exceed the maximum covered compensation of \$305 in 2022. Employees are eligible to participate in the Plan upon the completion of one year of service in which they have worked at least 1,000 hours. The participants have the option to direct these contributions into various funds offered through the Plan.

The Center and the Institute participate in City of Hope Research Staff Organization ("RSO") Tax Deferred Annuity Plan (the "RSO TDA Plan"), which was established in 1983 to provide benefits to eligible members of City of Hope RSO as defined in the plan document. Employer contributions of 15% of each participant's biweekly eligible salary are made up to a defined annual maximum base salary of \$305 in 2022. The participants have the option to direct these contributions into various funds offered through the RSO TDA Plan. Further, the subsidiaries (TGen, SCRO and the CTCA Entities) have their respective defined contribution profit sharing plans provided to eligible employees with matching contributions subject to certain eligibility criteria as stated in the plan document. Contribution expense for the plans defined totaled \$43,734 and \$35,483 for the fiscal years ended September 30, 2022 and 2021, respectively.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

13. Functional Classification of Expenses

City of Hope's primary program services consist of patient care, research, and public information and education. Expenses in general support of the program services of City of Hope are considered support services and include administrative and fundraising activities. Natural expenses that are attributable to more than one functional expense category are allocated using a variety of cost allocation methodologies, including headcount, square footage, and time and effort.

The expenses reported on the consolidated statements of activities supported the following programs and functions for the fiscal years ended September 30:

						Public ormation					
	1	Patient				and					
		Care	F	Research	Ec	ducation	Ad	lministrative	Fu	ndraising	Total
2022											
Salaries, wages, and employee benefits	\$	693,959	\$	305,332	\$	13,859	\$	327,323	\$	19,567	\$ 1,360,040
Purchased services and professional fees		335,450		156,298		17,173		255,099		14,400	778,420
Supplies and pharmaceuticals		993,877		77,530		856		21,840		8,419	1,102,522
Royalty sharing		7		6,409		_		_		_	6,416
Interest, including changes in fair											
value of swap agreements		11,281		1,951		173		2,427		_	15,832
Depreciation and amortization		100,074		43,297		1,329		49,559		511	194,770
Hospital provider fee		37,730		_		_		_		_	37,730
Other expense		83,007		59,059		15,852		109,185		5,637	272,740
Total expenses	\$ 2	,255,385	\$	649,876	\$	49,242	\$	765,433	\$	48,534	\$ 3,768,470

						Public ormation					
		Patient				and					
		Care	1	Research	E	ducation	A	dministrative	Fu	ndraising	Total
2021											
Salaries, wages, and employee benefits	\$	509,785	\$	264,923	\$	9,246	\$	216,350	\$	17,287	\$ 1,017,591
Purchased services and professional fees		253,274		100,163		3,243		176,034		18,545	551,259
Supplies and pharmaceuticals		531,729		61,257		188		7,309		3,948	604,431
Royalty sharing		21		36,585		_		_		_	36,606
Interest, including changes in fair											
value of swap agreements		22,317		5,241		259		4,496		_	32,313
Depreciation and amortization		72,616		33,364		856		46,488		75	153,399
Hospital provider fee		26,493		_		_		_		_	26,493
Other expense		60,545		26,201		4,875		34,687		1,897	128,205
Total expenses	\$ 1	1,476,780	\$	527,734	\$	18,667	\$	485,364	\$	41,752	\$2,550,297

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

14. Insurance Programs

Workers' Compensation Program

City of Hope, the Center, the Foundation, AH, and the Institute have elected to self-insure their workers' compensation liability. Reinsurance has been obtained for this program to cover claims that exceed \$250 between 1991 and 2002, \$500 in 2003, and \$1,000 per individual claim beginning in 2004. An estimated liability of \$23,958 and \$24,003 has been recorded as of September 30, 2022 and 2021, respectively. The estimated current portion of the liability, totaling \$4,605 and \$4,369 as of September 30, 2022 and 2021, respectively, is included in accrued salaries, wages, and employee benefits on the consolidated statements of financial position and the estimated long-term portion of the liability, totaling \$19,353 and \$19,634 as of September 30, 2022 and 2021, respectively, is included in other long-term liabilities on the consolidated statements of financial position. Accruals for uninsured claims and claims incurred but not reported are estimated by an actuary based on prior claims experience. The estimated liability was recorded using a 4% and 1% discount factor as of September 30, 2022 and 2021, respectively.

Expected insurance recoveries related to workers' compensation totaling \$3,632 and \$4,472 as of September 30, 2022 and 2021, respectively, have been reflected on the accompanying consolidated statements of financial position in other assets. Workers' compensation expense totaled \$6,848 and \$6,120 for the fiscal years ended September 30, 2022 and 2021, respectively.

Professional Liability Insurance

The Center, the Foundation, AH, and the Institute maintain professional liability insurance under a claims-made program, which provides coverage for claims arising out of incidents that have occurred from November 1, 1997 to September 30, 2022, with limits up to \$50,000 with a deductible of \$100 through June 30, 2014, and \$250 between July 1, 2014 and September 30, 2022. Accruals for uninsured claims and claims incurred but not reported are estimated by an actuary based on prior claims experience. Such accruals were recorded using a 4% and 1% discount factor as of September 30, 2022 and 2021, respectively. An estimated liability of \$2,273 and \$2,533 as of September 30, 2022 and 2021, respectively, is included within accounts payable and other accrued liabilities as well as other liabilities on the consolidated statements of financial position.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

14. Insurance Programs (continued)

The Center, the Foundation, AH, and the Institute recorded insurance recoveries related to professional liability totaling \$546 and \$743 as of September 30, 2022 and 2021, respectively, which have been reflected on the accompanying consolidated statements of financial position in other assets.

SCRO maintains health care professional liability insurance that provides coverage for claims arising that occurred from March 31, 2018 through September 30, 2022, with limits up to \$10,000 per occurrence and a deductible of \$10 for each claim.

The CTCA Entities maintain health care professional liability insurance that provides coverage for claims that occurred from February 2, 2022 through September 30, 2022, with limits up to \$40,000 and a deductible of \$1,000 in Arizona and Georgia and \$2,000 in Illinois for each claim.

The professional liability insurance expense included in other expense on the consolidated statements of activities amounted to \$1,982 and \$2,256 for the fiscal years ended September 30, 2022 and 2021, respectively.

15. Leases

City of Hope enters into right-of-use operating and finance leases primarily for buildings and equipment. For leases with terms greater than 12 months, City of Hope records the related right-of-use asset and liability at the present value of the lease payments over the contract term using a risk-free interest rate. City of Hope elected the practical expedient not to separate contract lease and non-lease components. Building lease agreements generally require City of Hope to pay maintenance, repairs, property taxes, and insurance costs, which are variable amounts based on actual costs incurred during each applicable lease period. Such costs are not included in the determination of right-of-use assets or liabilities. Variable lease costs also include escalating rent payments over the lease term based on changes in the Consumer Price Index or other measures of inflation.

Most leases include one or more options to renew the lease at the end of the initial term, with renewal terms that generally extend the lease at the then-market rate of rental payments. City of Hope does not include the renewal options in the lease term for calculating the lease liability due to the uncertainty at the time of lease commencement as to whether the renewal option is

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

15. Leases (continued)

reasonably certain to be executed. Certain leases also include an option to buy the underlying asset at or a short time prior to the termination of the lease. All such options are at City of Hope's discretion and are evaluated at the commencement of the lease, with only those options that are reasonably certain of exercise included in the determination of the appropriate lease term. The discount rates applied for existing leases uses various risk-free rates depending upon the lease term for right-of-use operating lease liabilities.

The weighted average lease term and discount rate are as follows as of September 30:

	2022	2021
Right-of-use operating leases remaining lease term Right-of-use finance leases remaining lease term	12.6 years 10.4 years	14.6 years 11.8 years
Right-of-use operating leases discount rate	1.7 %	1.6%
Right-of-use finance leases discount rate	3.5 %	3.5%

Lease expense for lease payments is recognized on a straight-line basis over the lease term. The components of lease expense and rent expense are as follows for the fiscal years ended September 30:

	 2022	2021
Right-of-use operating:		
Operating lease expense	\$ 28,990 \$	20,425
Variable lease expense	4,775	2,517
Short-term lease expense	2,325	2,821
Sublease income	(1,082)	(302)
Right-of-use finance:		
Amortization of leased assets	7,912	7,510
Interest on lease liabilities	2,012	2,100
Total lease expense	\$ 44,932 \$	35,071

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

15. Leases (continued)

Cash paid for amounts included in the measurement of lease liabilities for the fiscal years ended September 30 is as follows:

	2022			2021	
Operating cash flows for operating leases Operating cash flows for finance leases	\$	26,657 2,012	\$	12,556 2,143	
Financing cash flows for finance leases		10,009		7,363	

The following table summarizes the maturity of right-of-use lease liabilities under operating and finance leases for subsequent fiscal years as of September 30, 2022:

	 perating F	inancing
2023	\$ 30,061 \$	10,196
2024	21,161	9,666
2025	20,475	8,786
2026	16,376	4,875
2027	15,821	4,335
Thereafter	 127,091	28,519
Total lease payments	230,985	66,377
Less: interest	 (40,063)	(12,194)
Total lease liabilities	190,922	54,183
Less: current portion, lease liabilities	 (27,541)	(8,375)
Long-term portion, lease liabilities	\$ 163,381 \$	45,808

Right-of-Use Finance Lease Obligations – City of Hope has entered into various right-of-use finance lease agreements for equipment and program and administrative facilities. Finance lease obligations are capitalized using the rate implicit in the lease agreement if the rate is readily determinable. Otherwise, City of Hope uses the risk-free rate available on the commencement date of the lease.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

15. Leases (continued)

Assets Constructed by Landlord – Under ASC 842, *Leases*, a build to suit arrangement exists when a lessee owns or controls the underlying assets, or the lessor has an enforceable right to payment for its performance to date. If the lessee is determined to be the owner during the construction period, all costs incurred by the lessor to construct the asset will be recorded as construction-in-progress and a related long-term liability. Upon completion of construction, projects will be evaluated for sales leaseback treatment, and should the criteria not be met, City of Hope will carry and amortize the financing obligation to the extent that lease payments are applied to the liability and depreciate the building over the estimated useful life.

On October 23, 2018, the Foundation entered into a 15-year lease agreement with a developer for a medical office building. This lease was subject to build to suit accounting under ASC 840. With the adoption of ASC 842, effective October 1, 2019, this lease no longer qualifies as a build to suit under the new criteria. The Foundation expects to begin operating a multidisciplinary community cancer center at this location in 2021. As of September 30, 2021, City of Hope had not taken control of the space and the lease had not commenced. As of September 30, 2022, City of Hope took control of the Corona Medical Office Building, commencing the start of a lease agreement with a right-of-use asset and lease liability related to the lease recorded as of September 30, 2022.

16. Commitments and Contingencies

Medicare and Medicaid Laws and Regulations

City of Hope is reimbursed for services provided to patients under certain programs administered by governmental agencies. Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future governmental review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medicaid programs. City of Hope believes it is in compliance with all applicable laws and regulations, and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

16. Commitments and Contingencies (continued)

Collective Bargaining Agreements

City of Hope is subject to nine collective bargaining agreements related to certain members of its labor force. Approximately 50% of employees are covered under collective bargaining agreements as of September 30, 2022. Two of the nine agreements expired during the fiscal year ended September 30, 2022; a new agreement with the California Nurses Association was negotiated and is in effect through April 30, 2024 and the second agreement remains in negotiation and is expected to be renewed for one to three years. Five of the nine agreements will expire in the following year and shall be renegotiated prior to expiration.

Litigation and Administrative Actions

From time to time, City of Hope is subject to claims arising in the ordinary course of business. In the opinion of management, the ultimate resolution of legal proceedings and other claims currently pending will not have a material adverse effect on the consolidated financial position, statements of activities, or cash flows of City of Hope.

Health Care Regulations

City of Hope is subject to numerous laws and regulations of federal, state, and local governments. These laws and regulations include, but are not necessarily limited to, licensure, accreditation, governmental health care program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Federal laws prohibit submission of claims for reimbursement to the Medicare and Medicaid programs for services not rendered in accordance with applicable rules, laws, and regulations. Any overpayments received must be refunded to the government payor. Violation of these laws can result in substantial civil and criminal penalties and fines, including treble damages plus mandatory penalties of up to \$11 per claim, as well as possible debarment from future participation in government health care programs. Management believes that City of Hope is presently in compliance with fraud and abuse laws, as well as other applicable government laws and regulations. While no material regulatory inquiries about past or present conduct have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

16. Commitments and Contingencies (continued)

Capital Commitments (Unaudited)

As of September 30, 2022, City of Hope has committed to spend \$573,789 through 2023 and beyond for building renovations, multiple campus facility renovations, and various information technology projects.

17. Community Benefit Expense (Unaudited)

City of Hope supports a variety of programs and services that provide a direct benefit to its patients, as well as to the broader community. The primary categories of community benefit are as follows:

- Benefits for the Broader Community Clinical Research
- Benefits for the Broader Community Support of Basic Science Research
- Public Information and Education

City of Hope supports a variety of clinical and basic science research activities focused on finding cures and treatments for cancer and other life-threatening diseases and the development of diagnostics for which research grants, contracts, and clinical trial funding are not available.

The cost of these institutionally funded research efforts is considered a benefit to the broader community. In addition, the cost of providing public information and education is also considered a community benefit. The Center and the Foundation accept all patients who are covered by governmental subsidized programs – primarily Medicaid and Medicare fee for service, and who meet certain clinical criteria. These programs typically remit payments substantially less than charges and below the cost of providing the services. The Center and the Foundation have estimated the costs of treating patients less payments received for these costs. The residual amount of costs in excess of payments has been included as a component of community benefit.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

17. Community Benefit Expense (Unaudited) (continued)

The following is a summary of the estimated benefits for the broader community through internally funded research support and support of governmental health care programs – Medicaid and Medicare expense, at full cost, in terms of service to those patients covered under these programs for the fiscal years ended September 30:

	2022	2021
Benefits for the Broader Community – Support for		
Research (unaudited)		
Estimated institutionally supported research costs, net of grants received of \$214,403 and \$183,467 in 2022 and		
2021, respectively:		
Center	\$ 106,100 \$	122,306
Institute	237,186	214,615
TGen	53,803	46,458
Total estimated benefits for the broader community, at cost	397,089	383,379
Support of Governmental Health Care Programs (unaudited)		
Estimated unreimbursed cost of the Medicaid Program,		
less net impact of the hospital fee program of \$59,844		
and \$60,692 in 2022 and 2021, respectively	12,593	19,284
Estimated unreimbursed cost of the Medicare Program	233,476	188,054
	246,069	207,338
Total estimated benefits for the broader community and unreimbursed costs to governmental health care		
programs	\$ 643,158 \$	590,717

The numbers above exclude the CTCA Entities, primarily as HoldCo. was considered a for-profit organization prior to HoldCo's conversion to 501(c)(3) status at September 30, 2022.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

18. COVID-19 Pandemic

In March 2020, the World Health Development Organization declared the global novel coronavirus disease ("COVID-19") a pandemic. Following guidelines from federal, state, and local governments, City of Hope decided to postpone elective procedures; however, as a medical center primarily treating cancer, City of Hope has relatively fewer medical procedures that could be deferred. City of Hope continued to provide services for those patients whose treatment protocol could not be interrupted.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") was enacted in response to the COVID-19 emergency.

From April 2020 through January 2022, City of Hope received \$60,601 from the Department of Health and Human Services ("HHS") from the provider relief funds created under the CARES Act. City of Hope is not required to pay the funds received, as long as it agrees to comply with and attest to the terms and conditions specified by HHS. City of Hope was required to demonstrate that the distributions received have been used for health care related expenses or lost revenues attributable to COVID-19. Based on an analysis of the compliance and reporting requirements of the provider relief fund and the impact of the pandemic on City of Hope's operating results through September 30, 2022, City of Hope has attested to meeting the applicable terms and conditions required to retain all provider relief funds received as of the periods presented. As such, the table below sets forth a summary of the provider relief funds received and expended as of September 30:

Provider relief funds deferred as of September 30, 2020	\$ 5,548
Provider relief funds received	18,784
Revenue recognized as a result of satisfaction of terms and conditions	(24,332)
Provider relief funds deferred as of September 30, 2021	_
Provider relief funds received	12,630
Revenue recognized as a result of satisfaction of terms and conditions	(12,630)
Provider relief funds deferred as of September 30, 2022	\$ _

City of Hope will continue to monitor the terms and conditions of the CARES Act funding and the impact of COVID-19 on revenues and expenses. If City of Hope is unable to comply with future terms and conditions, the ability to retain some or all of the distributions received may be impacted.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

18. COVID-19 Pandemic (continued)

The Centers for Medicare & Medicaid Services ("CMS") expanded its Accelerated and Advance Payment Program to provide financial relief to Medicare providers that treat patients during the pandemic. The expansion of this program is limited to the duration of the pandemic and provides City of Hope with advance funding for future Medicare claims. Through September 30, 2022, City of Hope has received \$151,718 in advance payments. During the fiscal years ended September 30, 2022 and 2021, City of Hope applied \$102,404 and \$49,314, respectively, toward Medicare claims processed bringing the remaining balance to zero as of September 30, 2022.

City of Hope took advantage of the payroll tax deferral of the employer's share of Social Security tax, offered as a part of the COVID-19 relief program. This represented 6.2% of wages up to the current social security wage base (\$138 in 2020). The deferral is in effect for employer payroll taxes incurred between March 27, 2020 (the date of the enactment) and December 31, 2020. City of Hope is required to reimburse 50% of this deferral amount by December 31, 2021; the remaining 50% is due by December 31, 2022. This deferral provided additional current liquidity to City of Hope. As of September 30, 2021, City of Hope has deferred \$25,882 (50%, or \$12,941, which is shown in other in the long-term portion of total liabilities on the accompanying consolidated statements of financial position) and \$17,300, respectively, of payroll taxes that are recorded as accrued salaries, wages, and employee benefits on the accompanying consolidated statements of financial position. In December 2021, \$12,181 was paid with the remaining balance of \$13,701 deferred as of September 30, 2022.

City of Hope began experiencing gradual improvement in patient volumes in May and June 2021; at the same time, the delta variant of the coronavirus started to arise. States eased stay-at-home restrictions and announced plans to resume delayed health care services that could be deferred while City of Hope prepared for the COVID-19 surge. The COVID-19 pandemic continued to impact City of Hope's operations through September 30, 2022. The impact of the pandemic and continued emergence of various variants is expected to continue to affect City of Hope's operations and financial position, including market volatility on the investment portfolio, uncertainty in the labor market, and ongoing pressures felt in revenue generation and expense containment. COVID-19 could still negatively affect the operations and financial results of City of Hope as the pandemic continues and variants emerge, and the duration and extent of its impact are unknown.

Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

19. Sale of Subsidiary

During the fiscal year ended September 30, 2022, there was no disposal activity. During the fiscal year ended September 30, 2021, TGen entered into an agreement in February 2021 with Exact Sciences to sell Ashion Analytics, LLC ("Ashion Analytics"), through its wholly owned subsidiary, PMED Management, LLC for the purpose of accelerating worldwide patient care and precision medicine through sales channels and distribution networks. Regulatory approval was received and the sale was finalized in April 2021. TGen received gross proceeds of \$87,310, which was comprised of cash of \$72,000 and 125,444 common stock shares of Exact Sciences with a fair value on the acquisition date of the stock of \$15,310. TGen recorded a gain on the sale of Ashion Analytics of \$77,327, which is included on the accompanying consolidated statement of activities for the fiscal year ended September 30, 2021.

Additional contingent consideration totaling \$50,000 will be paid upon the achievement of specific commercial launch and cumulative revenue milestones, as defined in the agreement. The commercial launch milestone was evaluated as a derivative under ASC 815, *Derivatives and Hedging*, with no value recorded as of September 30, 2022, due to qualitative factors outside of TGen's control.

20. Subsequent Events

City of Hope has evaluated events occurring between September 30, 2022 and December 16, 2022, the date these consolidated financial statements were issued.

In October 2022 and November 2022, City of Hope has drawn a total of \$175,000 on its existing syndicated unsecured revolving line of credit (the April 2020 Line of Credit) of \$450,000. The proceeds will be used for general operating needs.

On November 10, 2022, City of Hope terminated three treasury rate lock agreements with an aggregate notional amount of \$261,000 that were tied to the underlying U.S. Treasury interest rate component of interest rate payments on anticipated debt issuances. These treasury rate lock agreements had an average fixed rate of 2.56%. The termination of the treasury rate lock agreements resulted in positive cash flow to City of Hope in the amount of \$59,044. This termination occurred concurrently with the pricing of the 2022 Notes described below.


Notes to Consolidated Financial Statements (continued) (Dollar Amounts Expressed in Thousands)

20. Subsequent Events (continued)

On November 10, 2022, City of Hope priced \$600,000 of taxable notes ("2022 Notes") that are expected to be purchased by six institutional investors. A portion of the 2022 Notes in the amount of \$525,000 was purchased on December 15, 2022 and will mature in tranches in the following amounts and dates, \$57,500 on November 15, 2027, \$175,000 on November 15, 2032, and \$292,500 on November 15, 2052. The remaining portion of the 2022 Notes in the amount of \$75,000 is expected to be purchased on January 18, 2023 and will mature on November 15, 2027. The 2022 Notes will be issued as obligations under the Obligated Group's Master Trust Indenture. The proceeds of the of the 2022 Notes will be used for general corporate purposes.

On November 15, 2022, the Illinois Finance Authority issued a \$650,000 taxable bond and loaned the proceeds to HoldCo pursuant to a loan agreement ("IFA Loan"). The proceeds of the IFA Loan were used to pay off a prior Bridge Loan entered into on January 31, 2022. The proceeds from the original Bridge Loan were used: (1) to finance the purchase of the CTCA Entities; (2) to provide working capital; and (3) for general corporate purposes. The IFA Loan matures on November 14, 2023. The IFA Loan is guaranteed by the Obligated Group and is secured by an obligation issued under the Obligated Group's Master Trust Indenture.

On November 16, 2022, City of Hope and its counterparty terminated one of two swap agreements previously entered into in February 2020, with a notional amount of \$71,355. The termination resulted in positive cash flow to City of Hope in the amount of \$8,181.





Ernst & Young LLP Suite 500 725 South Figueroa Street Los Angeles, CA 90017-5418 Tel: +1 213 977 3200 Fax: +1 213 977 3152

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

Management and The Board of Directors City of Hope

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the consolidated financial statements of City of Hope, which comprise the consolidated statements of financial position as of September 30, 2022 and 2021, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"), and have issued our report thereon dated December 16, 2022.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered City of Hope's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of City of Hope's internal control. Accordingly, we do not express an opinion on the effectiveness of City of Hope's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

2306-4265642



Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether City of Hope's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst + Young LLP

December 16, 2022

2306-4265642



Ernst & Young LLP Suite 500 725 South Figueroa Street Los Angeles, CA 90017-5418 Tel: +1 213 977 3200 Fax: +1 213 977 3152

ey.com

Report of Independent Auditors on Compliance for Each Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance

Management and The Board of Directors City of Hope

Report of Independent Auditors on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited City of Hope's compliance with the types of compliance requirements identified as subject to audit in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* that could have a direct and material effect on each of City of Hope's major federal programs for the year ended September 30, 2022. City of Hope's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, City of Hope complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended September 30, 2022.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of City of Hope and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on compliance for each major federal program. Our audit does not provide a legal determination of City of Hope's compliance with the compliance requirements referred to above.

2306-4265642



Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to City of Hope's federal programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on City of Hope's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about City of Hope's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, Government Auditing Standards, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and
 design and perform audit procedures responsive to those risks. Such procedures include
 examining, on a test basis, evidence regarding City of Hope's compliance with the
 compliance requirements referred to above and performing such other procedures as we
 considered necessary in the circumstances.
- Obtain an understanding of City of Hope's internal control over compliance relevant to the
 audit in order to design audit procedures that are appropriate in the circumstances and to
 test and report on internal control over compliance in accordance with the Uniform
 Guidance, but not for the purpose of expressing an opinion on the effectiveness of City of
 Hope's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

69 2306-4265642



Other Matters

The results of our auditing procedures disclosed an instance of noncompliance, which is required to be reported in accordance with the Uniform Guidance and which is described in the accompanying schedule of findings and questioned costs and identified below. Our opinion on each major federal program is not modified with respect to this matter.

Finding Number	Assistance Listing Numbers	Program Name	Compliance Requirement
Tullibei	Disting Numbers	1 Togram Name	Requirement
2022-001	10.025, 10.310, 12.351, 12.420, 12.910, 93.103, 93.113, 93.121, 93.172, 93.226, 93.242, 93.273, 93.286, 93.301, 93.307, 93.310, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.398,	Research and Development Cluster	I. Procurement and Suspension and Debarment
	93.399, 93.837, 93.838, 93.839, 93.847, 93.853,		
	93.855, 93.859, 93.865, 93.866, 93.867, 93.879		

Government Auditing Standards requires the auditor to perform limited procedures on City of Hope's response to the noncompliance finding identified in our audit described in the accompanying schedule of findings and questioned costs. City of Hope's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

City of Hope is responsible for preparing a corrective action plan to address each audit finding included in our auditor's report. City of Hope's corrective action plan was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on it.

Report on Internal Control Over Compliance

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance, and therefore, material weaknesses or significant deficiencies may exist that were not identified. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, as discussed below, we did identify a deficiency in internal control over compliance that we consider to be a significant deficiency.

2306-4265642 70



A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance. We consider the deficiency in internal control over compliance described in the accompanying schedule of findings and questioned costs and identified in the table below to be a significant deficiency.

Finding	Assistance	Program Name	Compliance
Number	Listing Numbers		Requirement
2022-001	10.025, 10.310, 12.351, 12.420, 12.910, 93.103, 93.113, 93.121, 93.172, 93.226, 93.242, 93.273, 93.286, 93.301, 93.307, 93.310, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.398, 93.399, 93.837, 93.838, 93.839, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.879	Research and Development Cluster	I. Procurement and Suspension and Debarment

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

Government Auditing Standards requires the auditor to perform limited procedures on City of Hope's response to the internal control over compliance finding identified in our audit described in the accompanying schedule of findings and questioned costs. City of Hope's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

City of Hope is responsible for preparing a corrective action plan to address each audit finding included in our auditor's report. City of Hope's corrective action plan was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on it.

71 2306-4265642



The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Ernst + Young LLP

June 30, 2023

Supplementary Information

Schedule of Expenditure of Federal Awards

Year Ended September 30, 2022

Federal Grantor/Program or Cluster Title/Pass-through Grantor	Assistance Listing Number	Pass-Through Grantor Identifying Number	Research and Development Cluster	Other Expenditures	Total Expenditures	Expenditures to Subrecipients
U.S. Department of Agriculture						
Plant and Animal Disease, Pest Control, and Animal Care						
Pass-through: Northern Arizona University	10.025	AP20VSSPRS00C117	\$ 36,966	\$ -	\$ 36,966	\$ -
Agriculture and Food Research Initiative (AFRI)	10.310		55,654	_	55,654	14,527
Pass-through: Medical College of Wisconsin	10.310	2020-67017-30843	30,736	_	30,736	_
Total 10.310			86,390	_	86,390	14,527
Total U.S. Department of Agriculture			123,356	_	123,356	14,527
U.S. Department of Defense						
Scientific Research - Combating Weapons of Mass Destruction						
Pass-through: Northern Arizona University	12.351	HDTRA1-17-10051	80,945	_	80,945	14,440
Pass-through: Northern Arizona University	12.351	HDTRA-1-18-0037	19,289	_	19,289	_
Total 12.351			100,234	-	100,234	14,440
Military Medical Research and Development	12.420		3,915,120	_	3,915,120	_
Pass-through: Northwestern University	12.420	W81XWH1710608	7,519	_	7,519	_
Pass-through: The University of Illinois at Chicago	12.420	W81XWH-18-1-0317	(567)	_	(567)	_
Pass-through: Mayo Clinic – Rochester	12.420	W81XWH-15-1-0293	45	_	45	_
Pass-through: The J. David Gladstone Institutes	12.420	W81XWH-15-9-001	61,280	_	61,280	_
Pass-through: Vanderbilt University	12.420	W81XWH-20-2-0046	12,916	_	12,916	_
Pass-through: Fred Hutchinson Cancer Research Center	12.420	W81XWH-19-1-0758	76,071	_	76,071	_
Pass-through: University of California, Riverside	12.420	W81XWH-19-1-0327	68,537	_	68,537	_
Pass-through: Mayo Clinic Arizona	12.420	W81XWH1910534	149,208	_	149,208	_
Total 12.420			4,290,129	_	4,290,129	_
Research and Technology Development						
Pass-through: Florida Institute For Human and Machine Cognition	12.910	FA8650-19-C-7944	906,836	_	906,836	_
Total U.S. Department of Defense			5,297,199	_	5,297,199	14,440

See accompanying notes to Schedule of Expenditures of Federal Awards.

Schedule of Expenditure of Federal Awards (continued)

Year Ended September 30, 2022

Federal Grantor/Program or Cluster Title/Pass-through Grantor	Assistance Listing Number	Pass-Through Grantor Identifying Number	Research and Development Cluster	Other Expenditures	Total Expenditures	Expenditures to Subrecipients
U.S. Department of Justice COVID-19 – COVID-19 Telehealth Program Total U.S. Department of Justice	32.006		\$ - -	\$ 188,777 188,777	\$ 188,777 188,777	\$ <u>-</u>
U.S. Department of Health and Human Services Food and Drug Administration Research Pass-through: Fred Hutchinson Cancer Research Center Pass-through: Arizona Department of Health Services Total 93.103	93.103 93.103	R01FD006836 U19FD007108	11,137 297,742 308,879	- - -	11,137 297,742 308,879	- - -
Environmental Health	93.113		359,481	-	359,481	64,203
Oral Diseases and Disorders Research Human Genome Research	93.121 93.172		23,462 692,366	-	23,462 692,366	_
Research on Healthcare Costs, Quality and Outcomes	93.226		419,747	-	419,747	59,526
Mental Health Research Grants Pass-through: University of Arizona Total 93.242	93.242 93.242	R01MH113407	181,585 (588) 180,997	_ 	181,585 (588) 180,997	_
Alcohol Research Programs Pass-through: Karolinska Institute Total 93.273	93.273 93.273	R01AA028549	121,152 249,082 370,234	- - -	121,152 249,082 370,234	_
Discovery and Applied Research for Technological Innovations to Improve Human Health Pass-through: California Institute of Technology	93.286	R01EB028277	57,591	-	57,591	_

See accompanying notes to Schedule of Expenditures of Federal Awards.

Schedule of Expenditure of Federal Awards (continued)

Year Ended September 30, 2022

	Assistance Listing	Pass-Through Grantor	Research and Development	Other	Total	Expenditures to
Federal Grantor/Program or Cluster Title/Pass-through Grantor	Number	Identifying Number	Cluster	Expenditures	Expenditures	Subrecipients
Small Rural Hospital Improvement Grant Program						
Pass-through: Duke University	93.301	U2COD023375	\$ 832	\$ -	\$ 832	\$ -
Minority Health and Health Disparities Research						
Pass-through: Fox Chase Cancer Center	93.307	R01MD013347	49,330	-	49,330	_
Trans-NIH Research Support	93.310		24,766	_	24,766	_
Pass-through: Massachusetts General Hospital	93.310	UG3TR002878	246,207	_	246,207	_
Pass-through: University of California San Diego Fetal Care and Genetics	93.310	UG3CA256960	(26,667)	_	(26,667)	_
Pass-through: Massachusetts General Hospital	93.310	UG3TR002878	338,685	_	338,685	_
Pass-through: Rhode Island Hospital	93.310	UH3OD023313	153,044	_	153,044	_
Pass-through: University of California, San Diego	93.310	UG3CA241687	170,751	_	170,751	_
Total 93.310			906,786	_	906,786	_
21st Century Cures Act – Beau Biden Cancer Moonshot						
Pass-through: Tufts University	93.353	U01CA224153	17,019	_	17,019	_
Pass-through: University of New Mexico	93.353	U2CCA252973	397,644	_	397,644	43,789
Total 93.353			414,663	_	414,663	43,789
Nursing Research	93.361		212,102	_	212,102	_
Pass-through: University of Colorado – Denver	93.361	U2CNR014637	137,118	_	137,118	_
Total 93.361			349,220	-	349,220	_

See accompanying notes to Schedule of Expenditures of Federal Awards.

75

Schedule of Expenditure of Federal Awards (continued)

Year Ended September 30, 2022

Federal Grantor/Program or Cluster Title/Pass-through Grantor	Assistance Listing Number	Pass-Through Grantor Identifying Number	Research and Development Cluster	Other Expenditures	Total Expenditures	Expenditures to Subrecipients
reactar Grantor/110gram of Cluster Titte/1 uss-un ough Grantor	rumper	ruentrying rumber	Cluster	Expenditures	Expenditures	Subrecipients
Cancer Cause and Prevention Research	93.393		\$ 9,875,736	\$ -	\$ 9,875,736	\$ 1,273,408
Pass-through: Baylor College of Medicine	93.393	U01CA170930	(13)	_	(13)	_
Pass-through: Georgetown University	93.393	R01CA129769	936	_	936	_
Pass-through: Dana-Farber Cancer Institute	93.393	R01CA216273	198,795	_	198,795	_
Pass-through: University of Alabama at Birmingham	93.393	U01CA213140	83,024	_	83,024	_
Pass-through: H. Lee Moffitt Cancer Center	93.393	R01CA219389	86,723	_	86,723	_
Pass-through: Fred Hutchinson Cancer Research Center	93.393	U01CA173642	32,723	_	32,723	_
Pass-through: St. Jude Children's Research Hospital	93.393	U54CA243124	161,612	_	161,612	_
Pass-through: The Wistar Institute	93.393	R01CA238457	75,602	_	75,602	_
Pass-through: Trustees of Boston University	93.393	R01CA249982	168,543	_	168,543	_
Pass-through: Northern Arizona University	93.393	R21CA248804	99,938	_	99,938	_
Total 93.393		·	10,783,619	-	10,783,619	1,273,408
Cancer Detection and Diagnosis Research	93.394		2,271,849	_	2,271,849	231,743
Pass-through: St. Jude Children's Research Hospital	93.394	R01CA193478	(1,615)	_	(1,615)	_
Pass-through: University of Nebraska Medical Center	93.394	R01CA218545	66,321	_	66,321	_
Pass-through: Mayo Clinic – Jacksonville	93.394	R01CA237602	38,539	_	38,539	_
Pass-through: The Children's Hospital of Philadelphia	93.394	R01CA254955	159,532	_	159,532	_
Pass-through: University of California San Diego Fetal Care and Genetics	93.394	R01CA228147	68,283	_	68,283	_
Pass-through: Rensselaer Polytechnic Institute	93.394	R01CA250636	30,595	_	30,595	_
Total 93.394		•	2,633,504	_	2,633,504	231,743

See accompanying notes to Schedule of Expenditures of Federal Awards.

76

Schedule of Expenditure of Federal Awards (continued)

Year Ended September 30, 2022

	Assistance	n Ti LC 1	Research and	Od	T 4.1	Expenditures
Federal Grantor/Program or Cluster Title/Pass-through Grantor	Listing Number	Pass-Through Grantor Identifying Number	Development Cluster	Other Expenditures	Total Expenditures	to Subrecipients
Cancer Treatment Research	93.395		\$ 14,113,168	\$ -	\$ 14,113,168	\$ 1,658,749
Pass-through: University of California, Irvine	93.395	U10CA027469	2,010	_	2,010	_
Pass-through: Seattle Children's Research Institute	93.395	R01CA175216	6,012	_	6,012	_
Pass-through: Ohio State University	93.395	R01CA201382	13,209	_	13,209	_
Pass-through: University of California San Diego Fetal Care and Genetics	93.395	R01CA206911	86,954	_	86,954	_
Pass-through: University of Nebraska Medical Center	93.395	P01CA229100	166,918	_	166,918	_
Pass-through: Brigham and Women's Hospital	93.395	P01CA163205	254,798	_	254,798	_
Pass-through: Mount Sinai School of Medicine	93.395	R01CA207446	26,339	_	26,339	_
Pass-through: University of Nebraska Medical Center	93.395	R01CA247471	125,145	_	125,145	_
Pass-through: University of Nebraska Medical Center	93.395	UH3CA206127	84,801	_	84,801	_
Pass-through: UPMC Hillman Cancer Center	93.395	U24CA247643	171,317	_	171,317	_
Pass-through: Oregon Health and Science University	93.395	U10CA180888	16,625	_	16,625	_
Pass-through: The George Washington University	93.395	UM1CA181255	44,523	_	44,523	_
Pass-through: University of Nebraska Medical Center	93.395	U01CA253218	78,832	_	78,832	_
Pass-through: Ohio State University	93.395	R01CA262388	206,114	_	206,114	_
Pass-through: University of Southern California	93.395	R01CA248381	48,212	_	48,212	_
Pass-through: University of Wisconsin	93.395	R01CA262292	23,583	_	23,583	_
Pass-through: St. Jude Children's Research Hospital	93.395	U24CA055727	32,301	_	32,301	_
Pass-through: American College of Radiology	93.395	U10CA021661	(53,651)	_	(53,651)	_
Total 93.395		•	15,447,210	_	15,447,210	1,658,749

See accompanying notes to Schedule of Expenditures of Federal Awards.

Schedule of Expenditure of Federal Awards (continued)

Year Ended September 30, 2022

Federal Grantor/Program or Cluster Title/Pass-through Grantor	Assistance Listing Number	Pass-Through Grantor Identifying Number	Research Develop Clust	ment	Other Expenditures	Total Expenditures	Expenditures to Subrecipients
Cancer Biology Research	93.396		\$ 7.98	5,323	¢	\$ 7,985,323	\$ 189,935
Pass-through: University of Nebraska Medical Center	93.396	R01CA244900	-	9,323	5 –	89,323	\$ 109,933
Pass-through: University of Nebraska Medical Center Pass-through: University of California San Diego Fetal Care and Genetics	93.396	R01CA212119		6,138	_	46,138	_
Pass-through: Dana-Farber Cancer Institute	93.396	P01CA233412		0,508		180,508	
Pass-through: University of Nebraska Medical Center	93.396	R01CA251412		6,811		226,811	
Pass-through: Cleveland Clinic	93.396	P01CA245705		2,393	_	392,393	_
Pass-through: Northern California Institute for Research and Education	93.396	UG3 CA241703		2,989	_	142,989	_
Pass-through: University of California, San Diego	93.396	R35 CA197699		5,653	_	75,653	_
Total 93.396	75.570	100 01119,099		9,138	_	9,139,138	189,935
Cancer Centers Support Grants	93.397		8,09	6,642	_	8,096,642	1,055,338
Pass-through: University of California, Los Angeles	93.397	P50CA092131	9	2,407	_	92,407	_
Total 93.397			8,18	9,049	-	8,189,049	1,055,338
Cancer Research Manpower	93.398		3,32	3,779	_	3,323,779	_
Pass-through: Johns Hopkins Medical Institutions	93.398	R25CA225485	5	4,653	_	54,653	_
Total 93.398			3,37	8,432	-	3,378,432	_
Cancer Control							
Pass-through: Virginia Commonwealth University	93.399	P20CA252717	15	7,322	-	157,322	_
COVID-19 – Provider Relief Fund and American Rescue Plan (ARP)							
Rural Distribution	93.498			_	18,796,115	18,796,115	_

See accompanying notes to Schedule of Expenditures of Federal Awards.

Schedule of Expenditure of Federal Awards (continued)

Year Ended September 30, 2022

	Assistance		Re	search and			Exp	enditures
	Listing	Pass-Through Grantor	De	evelopment	Other	Total		to
Federal Grantor/Program or Cluster Title/Pass-through Grantor	Number	Identifying Number		Cluster	Expenditures	Expenditures	Sub	recipients
					_		_	
Cardiovascular Diseases Research	93.837		\$	7,430,194	\$ -	\$ 7,430,194	\$	3,818,069
Pass-through: Vanderbilt University	93.837	P01HL129941		11,518	_	11,518		_
Pass-through: University of California San Diego Fetal Care and Genetics	93.837	R01HL108735		(43,354)	_	(43,354)		_
Pass-through: Vanderbilt University	93.837	R35HL140016		61,413	_	61,413		_
Pass-through: University of Pennsylvania	93.837	R21HL150723		17,443	_	17,443		_
Pass-through: Massachusetts General Hospital	93.837	R35HL150807		83,437	_	83,437		_
Pass-through: University of Iowa – Pathology	93.837	R01HL147545		88,873	_	88,873		_
Pass-through: University of California San Diego Fetal Care and Genetics	93.837	R01HL108735		104,038	_	104,038		_
Pass-through: University Of Arizona	93.837	R01HL153112		17,469	_	17,469		_
Total 93.837				7,771,031	_	7,771,031		3,818,069
Lung Diseases Research	93.838			666,064	_	666,064		194,481
Pass-through: University of Virginia	93.838	R01HL132177		19,999	_	19,999		_
Pass-through: University of Southern California	93.838	R01HL114959		82,856	_	82,856		_
Total 93.838				768,919	_	768,919		194,481
Blood Diseases and Resources Research	93.839			1,184,946	_	1,184,946		_
Pass-through: Indiana University	93.839	R01HL111656		23,430	_	23,430		_
Pass-through: National Marrow Donor Program	93.839	1703		1,029	_	1,029		_
Pass-through: National Marrow Donor Program	93.839	1702		1,452	_	1,452		_
Total 93.839				1,210,857	-	1,210,857		_

See accompanying notes to Schedule of Expenditures of Federal Awards.

Schedule of Expenditure of Federal Awards (continued)

Year Ended September 30, 2022

	Assistance Listing	Pass-Through Grantor	Research and Development	Other	Total	Expenditures to
Federal Grantor/Program or Cluster Title/Pass-through Grantor	Number	Identifying Number	Cluster	Expenditures	Expenditures	Subrecipients
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847		\$ 12,034,556	\$ -	\$ 12,034,556	\$ 1,159,547
Pass-through: University of Minnesota Medical Center	93.847	R01DK121019	127,508	_	127,508	_
Pass-through: Augusta University	93.847	U24DK076169	2	_	2	_
Pass-through: University of Minnesota Medical Center	93.847	R01DK121019	55,256	_	55,256	_
Pass-through: 21st Century Medicine	93.847	R43DK117782	33,915	_	33,915	_
Pass-through: Tulane University	93.847	R01DK128907	215,144	_	215,144	_
Pass-through: University of Pittsburgh	93.847	R01DK130499	39,434	_	39,434	_
Pass-through: University of Utah	93.847	U24DK115255	18,202	_	18,202	_
Pass-through: University of California San Diego Fetal Care and Genetics	93.847	R01DK114945	23,934	_	23,934	_
Total 93.847			12,547,951	_	12,547,951	1,159,547
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853		1,088,588	_	1,088,588	15,738
Pass-through: University of Pittsburgh	93.853	R56NS113810	(2,446)	_	(2,446)	_
Pass-through: Virginia Polytechnic Institute and State	93.853	R01NS115971	348,184	_	348,184	_
Pass-through: University of Pittsburgh	93.853	R01NS121037	170,425	_	170,425	_
Pass-through: Saint Joseph's Hospital and Medical Center	93.853	R01NS120331	254,934	_	254,934	_
Pass-through: Saint Joseph's Hospital and Medical Center	93.853	R21NS116385	29,683	_	29,683	_
Pass-through: Saint Joseph's Hospital and Medical Center	93.853	R21NS125861	33,355	_	33,355	_
Pass-through: University of Arizona	93.853	R01NS091299	19,705	_	19,705	_
Total 93.853			1,942,428	_	1,942,428	15,738

See accompanying notes to Schedule of Expenditures of Federal Awards.

Schedule of Expenditure of Federal Awards (continued)

Year Ended September 30, 2022

	Assistance		R	esearch and			Expenditures
	Listing	Pass-Through Grantor	D	evelopment	Other	Total	to
Federal Grantor/Program or Cluster Title/Pass-through Grantor	Number	Identifying Number		Cluster	Expenditures	Expenditures	Subrecipients
					_		
Allergy and Infectious Diseases Research	93.855		\$	3,376,694	\$ -	\$ 3,376,694	\$ 454,630
Pass-through: Scripps Research Institute	93.855	P01AI099783		(427)	_	(427)	-
Pass-through: University of California, Los Angeles	93.855	U19AI128913		7,514	_	7,514	_
Pass-through: Cedars-Sinai Medical Center	93.855	R01AI134714		(10,849)	_	(10,849)	_
Pass-through: University of California, Los Angeles	93.855	UM1AI068636		318,495	_	318,495	_
Pass-through: The J. David Gladstone Institutes	93.855	R37AI109593		272,128	_	272,128	-
Pass-through: University of Washington	93.855	U01AI163090		386,666	_	386,666	_
Pass-through: Children's Hospital Boston	93.855	U24AI152179		63,155	_	63,155	_
Pass-through: University of California, San Francisco	93.855	R01AI121144		2,100	_	2,100	_
Pass-through: University of California, San Francisco	93.855	R01AI131939		237,741	_	237,741	-
Pass-through: University of California, San Francisco	93.855	R01AI153213		30,144	_	30,144	-
Pass-through: University of California, San Francisco	93.855	R21AI152564		90,653	_	90,653	-
Pass-through: University of Cape Town	93.855	R01AI147346		26,613	_	26,613	_
Pass-through: Yale University	93.855	R01AI147854		329,168	_	329,168	-
Total 93.855				5,129,795	-	5,129,795	454,630
Biomedical Research and Research Training	93.859			1,132,670	_	1,132,670	41,369
Pass-through: Virginia Polytechnic Institute and State	93.859	R01GM141096		18,808	_	18,808	_
Total 93.859				1,151,478	_	1,151,478	41,369
Child Health and Human Development Extramural Research	93.865			151,223	_	151,223	_

See accompanying notes to Schedule of Expenditures of Federal Awards.

Schedule of Expenditure of Federal Awards (continued)

Year Ended September 30, 2022

Federal Grantor/Program or Cluster Title/Pass-through Grantor	Assistance Listing Number	Pass-Through Grantor Identifying Number	esearch and evelopment Cluster	Other Expenditures	Total Expenditures	Expenditures to Subrecipients
Aging Research	93.866		\$ 3,580,647	\$ -	\$ 3,580,647	\$ 990,012
Pass-through: Brigham and Women's Hospital	93.866	R01AG060539	836	_	836	_
Pass-through: Duke University	93.866	U01AG034661	65,661	_	65,661	_
Pass-through: Johns Hopkins Medical Institutions	93.866	UH3AG056933	129,432	_	129,432	_
Pass-through: Arizona State University	93.866	R01AG059627	101,943	_	101,943	_
Pass-through: Banner Health	93.866	P30AG019610	34,399	_	34,399	_
Pass-through: Banner Health	93.866	P30AG072980	14,097	_	14,097	_
Pass-through: Banner Health	93.866	R01AG069453	83,099	_	83,099	_
Pass-through: California Pacific Medical Center Research Institute	93.866	U19 AG023122	493,448	_	493,448	81,260
Pass-through: Jackson Laboratory	93.866	R01AG054180	8,590	_	8,590	_
Pass-through: Northwestern University	93.866	R01AG067781	89,263	_	89,263	_
Pass-through: Northwestern University	93.866	U19AG073153	200,508	_	200,508	22,374
Pass-through: The University of Alabama at Birmingham	93.866	R01AG075059	4,757	_	4,757	_
Pass-through: University of Arizona	93.866	R01AG072643	148,619	_	148,619	_
Pass-through: University of Arizona	93.866	R56AG068098	31,680	_	31,680	_
Pass-through: University of Arizona	93.866	U19AG065169	1,770,295	_	1,770,295	_
Pass-through: University of Florida	93.866	R01AG057764	55,688	_	55,688	_
Total 93.866			6,812,962	-	6,812,962	1,093,646
Vision Research						
Pass-through: University of New Mexico	93.867	R01EY028606	273,375	-	273,375	-
Medical Library Assistance	93.879		277,114	_	277,114	_
Total U.S. Department of Health and Human Services			91,898,995	18,796,115	110,695,110	11,354,171
Total Expenditures of Federal Awards			\$ 97,319,550	\$ 18,984,892	\$ 116,304,442	\$ 11,383,138

See accompanying notes to Schedule of Expenditures of Federal Awards.

Notes to Schedule of Expenditures of Federal Awards

Year Ended September 30, 2022

1. Summary of Significant Accounting Policies

Basis of Accounting

The accompanying Schedule of Expenditures of Federal Awards (SEFA) includes the federal grant activity of City of Hope and is presented on the accrual basis of accounting. The information in the SEFA is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in the SEFA may differ from amounts presented in, or used in the preparation of, the consolidated financial statements of City of Hope. For purposes of the SEFA, federal awards include any assistance provided by a federal agency, directly, or indirectly, in the form of grants, contracts, cooperative agreements, loan and loan guarantees, or other non-cash assistance. Negative amounts shown in the SEFA represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. The SEFA does not include payments received under the traditional Medicare and Medicaid reimbursement programs, as these programs are outside the scope of the Uniform Guidance. There were no donated goods and personal protective equipment received from federal sources that required recognition or disclosure in the notes to the SEFA.

2. Indirect Costs

City of Hope does not use the 10 percent de minimis indirect cost rate provided for in the Uniform Guidance.

Notes to Schedule of Expenditures of Federal Awards (continued)

Year Ended September 30, 2022


3. Provider Relief Fund

The amount presented on the SEFA for Assistance Listing Number 93.498, COVID-19 – Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution (PRF Funds), is for the year ended September 30, 2022. The amount presented reconciles to the Provider Relief Fund (PRF) information reported to the Health Resources and Services Administration (HRSA) as follows:

Name of reporting entity for HRSA Reporting Period 2 PRF Report	Reporting Entity Tax Identification Number	Total Other Provider Relief Type of Fund Expenses Distribution Reported			Total Lost Revenues Reported	Total		
City of Hope	953435919	General	\$ \$	3,491,860 3,491,860	\$ \$	15,304,255 15,304,255	\$	18,796,115 18,796,115

Health and Human Services (HHS) has indicated the PRF Funds on the SEFA be reported corresponding to reporting requirements of the HRSA PRF Reporting Portal. Payments from HHS for PRF are assigned to 'Payment Received Periods' (each, a Period) based upon the date each payment from the PRF was received. Each Period has a specified Period of Availability and timing of reporting requirements. Entities report into the HRSA PRF Reporting Portal after each Period's deadline to use the funds (i.e., after the end of the Period of Availability).

The SEFA includes \$18,796,115 of PRF Funds received from HHS between July 1, 2020 through June 30, 2021. In accordance with guidance from HHS, these amounts are presented as Period 2. Such amount was recognized as other revenue in City of Hope's consolidated financial statements in the year ended September 30, 2021.



Schedule of Findings and Questioned Costs

Year Ended September 30, 2022

Section I – Summary of Auditor's Results

Financial Statements

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP:	Unmodified				
Internal control over financial reporting:					
Material weakness(es) identified?	Yes	X_No			
Significant deficiency(ies) identified?	Yes	X None reported			
Noncompliance material to financial statements noted?	Yes	X No			
Federal Awards					
Internal control over major federal programs:					
Material weakness(es) identified?	Yes	X No			
Significant deficiency(ies) identified?	XYes	None reported			
Type of auditor's report issued on compliance for major federal programs:	,	Unmodified			
Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200 516(a)?	X_Yes	No			

85

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section I – Summary of Auditor's Results (continued)

Identification of major federal programs:

Assistance Listing Numbers	Name of Federal Program or Cluster				
10.025, 10.310, 12.351, 12.420, 12.910, 93.103, 93.113, 93.121, 93.172, 93.226, 93.242, 93.273, 93.286, 93.301, 93.307, 93.310, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.398, 93.899, 93.837, 93.838, 93.839, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.879	Research and Development Cluster				
93.498	COVID-19 – Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution				
Dollar threshold used to distinguish between Type A and Type B programs:	\$3,000,000				
Auditee qualified as low-risk auditee?	X_YesNo				
Section II – Financial Statement Findings					
No matters were reported.					

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs

Finding 2022-001

Internal control deficiency and noncompliance over Procurement and Suspension and Debarment.

Identification of the federal program:

Research and Development Cluster

Assistance Listing					
Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
10.025	Plant and Animal Disease, Pest Control, and Animal Care	U.S. Department of Agriculture	AP20VSSPRS00C117	October 1, 2020 to August 31, 2022	Northern Arizona University
10.310		-	2017-67017-26570	June 1, 2017 to May 31, 2020	-
	Agriculture and Food		2020-67017-30843	April 20, 2020 to April 19, 2023	
	Research Initiative (AFRI)	U.S. Department of Agriculture	2018-67017-27875	April 15, 2021 to April 14, 2023	Medical College of Wisconsin
12.351	Scientific Research -		HDTRA1-17-10051	August 10, 2017 to February 28, 2022	
	Combating Weapons of Mass Destruction	U.S. Department of Defense	HDTRA-1-18-0037	July 3, 2020 to December 31, 2021	Northern Arizona University
12.420			W81XWH-16-1-0641	September 30, 2016 to September 29, 2021	
			W81XWH-18-1-0205	September 1, 2018 to August 31, 2021	
			W81XWH-19-1-0310	August 1, 2019 to July 31, 2023	
			W81XWH-19-1-0593	September 30, 2019 to September 29, 2022	
			W81XWH-19-1-0754	September 1, 2019 to August 31, 2022	
			W81XWH-19-1-0852	September 30, 2019 to September 29, 2022	
			W81XWH-19-1-0326	September 1, 2019 to August 31, 2023	
			W81XWH-20-1-0613	September 1, 2020 to August 31, 2023	
			W81XWH-20-1-0401	September 1, 2020 to August 31, 2022	
			W81XWH-20-10362	September 1, 2020 to August 31, 2022	
	Military Medical	H.C. Damartunani, C.	W81XWH-21-1-0038	January 1, 2021 to December 31, 2022	
	Research and Development	U.S. Department of Defense	W81XWH-21-1-0354	June 1, 2021 to May 31, 2024	

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance					
Listing					
Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
				February 1, 2022 to	
			W81XWH-22-1-0031	January 31, 2025	
				May 15, 2022 to May 14,	
			W81XWH-22-1-0402	2025	
			W01XWH 22 1 0207	June 15, 2022 to June 14,	
			W81XWH-22-1-0397	2023 September 1, 2022 to	
			W01VWII 22 1 0221	1 '	
			W81XWH-22-1-0331	August 31, 2023 June 1, 2017 to May 31,	
			W81XWH-17-0151	2022	
			W01AW11-17-0151	September 15, 2018 to	
			W81XWH-18-1-0617	September 14, 2023	
			W0124W11 10 1 0017	July 1, 2019 to June 30,	
			W81XWH-19-10277	2022	
				August 1, 2019 to July 31,	
			W81XWH1910416	2023	
				September 15, 2017 to	Northwestern
			W81XWH1710608	September 14, 2021	University
				July 15, 2018 to July 14,	The University of
			W81XWH-18-1-0317	2021	Illinois at Chicago
				July 1, 2019 to	Mayo Clinic –
			W81XWH-15-1-0293	September 29, 2022	Rochester
				June 5, 2020 to	The J. David
			W81XWH-15-9-001	December 31, 2022	Gladstone Institutes
			****************	September 2, 2020 to	
			W81XWH-20-2-0046	September 1, 2022	Vanderbilt University
				S	Fred Hutchinson
			W81XWH-19-1-0758	September 15, 2020 to	Cancer Research Center
			W 81 A W II-19-1-0/38	September 14, 2022 September 1, 2021 to	University of
			W81XWH-19-1-0327	August 31, 2023	California, Riverside
			W 01 X W 11-19-1-0327	September 1, 2019 to	Camonna, Kiveisiue
			W81XWH1910534	August 31, 2023	Mayo Clinic Arizona
12.910	Research and		5111 ((111) 10554	1145451 51, 2025	Florida Institute For
12.510	Technology	U.S. Department of		September 1, 2019 to	Human and Machine
	Development	Defense	FA8650-19-C-7944	February 28, 2022	Cognition
93.103	•				Fred Hutchinson
				August 24, 2020 to	Cancer Research
	Food and Drug	U.S. Department of	R01FD006836	March 31, 2022	Center
	Administration_Rese	Health and Human		September 1, 2020 to	Arizona Department
	arch	Services	U19FD007108	June 30, 2025	of Health Services
93.113				September 30, 2015 to	
		U.S. Department of	U01ES026137	June 30, 2021	
	E	Health and Human	DOIDGOGG 112	September 2, 2021 to	37/4
02.121	Environmental Health	Services	R01ES033413	June 30, 2026	N/A
93.121	Orol Dioc 1	U.S. Department of		Angust 5, 2016 to Tolo 21	
	Oral Diseases and	Health and Human Services	D01DE026204	August 5, 2016 to July 31, 2022	N/A
	Disorders Research	Services	R01DE026304	2022	IN/A

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance					
Listing					
Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
93.172		Hab	D25HC010721	July 1, 2019 to June 30,	
	Human Genome	U.S. Department of Health and Human	R35HG010721	2024 September 15, 2022 to	
	Research	Services	R01HG011886	June 30, 2026	N/A
93.226	Research on	Services	KUIHGUI1000	April 1, 2018 to	IN/A
93.220	Healthcare Costs,	U.S. Department of	R01HS024917	December 14, 2022	
	Quality and	Health and Human	101115021717	December 15, 2020 to	
	Outcomes	Services	R01HS024917-S1	December 14, 2022	N/A
93.242		277.177		April 1, 2017 to	
		U.S. Department of	R01MH113407	February 28, 2023	
	Mental Health	Health and Human		December 1, 2012 to	1
	Research Grants	Services	R01MH097803	October 31, 2023	University of Arizona
93.273				November 1, 2017 to	
		U.S. Department of	K08AA025112	April 30, 2023	
	Alcohol Research	Health and Human		September 20, 2020 to	
	Programs	Services	R01AA028549	June 30, 2025	Karolinska Institute
93.286	Discovery and				
	Applied Research for Technological				
	Innovations to	U.S. Department of			
	Improve Human	Health and Human		July 1, 2019 to March 31,	California Institute of
	Health	Services	R01EB028277	2023	Technology
93.301	Small Rural Hospital	U.S. Department of			211111111111111111111111111111111111111
	Improvement Grant	Health and Human		September 21, 2016 to	
	Program	Services	U2COD023375	August 31, 2023	Duke University
93.307	Minority Health and	U.S. Department of			
	Health Disparities	Health and Human		September 1, 2018 to	Fox Chase Cancer
	Research	Services	R01MD013347	March 31, 2022	Center
93.310			***************************************	September 1, 2020 to	
			UH3CA213385-S1	August 31, 2022	36 1
			11C2TD002070	September 16, 2019 to	Massachusetts
			UG3TR002878	June 30, 2023	General Hospital University of
					California San Diego
				September 11, 2020 to	Fetal Care and
			UG3CA256960	August 31, 2021	Genetics
				September 21, 2016 to	
		U.S. Department of	UH3OD023313	August 31, 2023	Rhode Island Hospital
	Trans-NIH Research	Health and Human		September 1, 2019 to	University of
	Support	Services	UG3CA241687	August 31, 2023	California, San Diego
93.353				September 30, 2017 to	
	21st Century Cures	U.S. Department of	U01CA224153	August 31, 2022	Tufts University
	Act - Beau Biden	Health and Human	11000 1050050	September 2, 2020 to	University of New
02.261	Cancer Moonshot	Services	U2CCA252973	August 31, 2026	Mexico
93.361		II C Domeston and a C	DO1NDO15241	September 28, 2014 to	
		U.S. Department of Health and Human	R01NR015341	June 30, 2019 April 14, 2021 to	University of
	Nursing Research	Services	R21NR019866	April 14, 2021 to March 31, 2023	University of Colorado – Denver
	runsing Research	Services	K211NKU17000	Wiaicii 51, 2025	Colorado – Deliver

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance					
Listing					
Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
				July 1, 2018 to June 30,	
			U2CNR014637	2023	
93.393				September 1, 2014 to	
			R25CA160049	August 31, 2016	
			D04G440EE04	April 1, 2016 to March 31,	
			R01CA197506	2022	
			D01GA202712	August 1, 2016 to July 31,	
			R01CA202712	2023 August 1, 2017 to July 31,	
			D01CA072764		
			R01CA073764	2023 August 1, 2017 to July 31,	
			R01CA220693	2022	
			K01CA220093	July 4, 2017 to	
			R01CA164019	December 31, 2021	
			ROTCHTO-017	September 18, 2018 to	
			R01CA217841	August 31, 2023	
			1101011217011	December 3, 2018 to	
			R37CA233691	November 30, 2023	
				February 1, 2019 to	
			R01CA225843	January 31, 2024	
				May 1, 2019 to April 30,	
			R01CA085344	2025	
				June 1, 2019 to May 31,	
			R01CA240392	2024	
				June 1, 2019 to July 31,	
			U01CA214254	2023	
				September 1, 2019 to	
			R01CA130899	August 31, 2024	
				September 18, 2019 to	
			R01CA242218	August 31, 2024	
				December 2, 2019 to	
			R01CA233664	November 30, 2024	
			D01GA107250	February 1, 2020 to	
			R01CA197350	July 31, 2022	
			D01CA217941 C1	September 1, 2020 to	
			R01CA217841-S1	August 31, 2022 September 9, 2020 to	
			U01CA199277	August 31, 2025	
			001CA133211	July 1, 2021 to June 30,	
			R01CA256989	2026	
			101011230707	July 1, 2021 to June 30,	
			R21CA261797	2023	
				September 20, 2021 to	
			R50CA211397	August 31, 2026	
			·	September 1, 2021 to	
		U.S. Department of	3U01CA199277-07S1	August 31, 2022	
	Cancer Cause and	Health and Human	<u> </u>	March 10, 2022 to	
	Prevention Research	Services	R21CA270862	February 29, 2024	

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance					
Listing					
Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
				July 5, 2022 to June 30,	
			R01CA261793	2027	
				July 1, 2022 to June 30,	
			R03CA267445	2024	
				August 1, 2013 to July 31,	Baylor College of
			U01CA170930	2019	Medicine
				September 1, 2015 to	Georgetown
			R01CA129769	November 30, 2021	University
				July 1, 2017 to April 30,	Dana-Farber Cancer
			R01CA216273	2022	Institute
					University of
			1101 (14 2121 40	April 1, 2019 to March 31,	Alabama at
			U01CA213140	2024	Birmingham
			D01G101000	June 1, 2018 to	H. Lee Moffitt Cancer
			R01CA219389	February 28, 2023	Center
				g , 1 10 2010 ;	Fred Hutchinson
			1101CA 172CA2	September 19, 2019 to	Cancer Research Center
			U01CA173642	March 31, 2022 September 19, 2019 to	St. Jude Children's
			1154CA242124	August 31, 2024	
			U54CA243124	September 15, 2020 to	Research Hospital
			R01CA238457	November 30, 2022	The Wistar Institute
			K01CA230437	June 1, 2021 to May 31,	Trustees of Boston
			R01CA249982	2023	University
			R01CA2+7702	May 1, 2021 to April 30,	Northern Arizona
			R21CA248804	2023	University
93.394			1121 0112 1000 1	July 1, 2015 to	Chrycisty
,,,,,,			R01CA197359	December 31, 2020	
				October 1, 2015 to July 31,	
			U01CA189283	2023	
				July 1, 2018 to June 30,	
			R01CA197359-S1	2020	
				August 1, 2018 to July 31,	
			R01CA174294	2022	
				February 1, 2019 to	
			R21CA236057	December 31, 2022	
				April 5, 2019 to	
			R21CA228542	October 31, 2022	
				July 1, 2019 to June 30,	
			R01CA184792	2022	
				June 1, 2019 to July 31,	
			R01CA072851	2022	
				June 1, 2019 to July 31,	
			R01CA202797	2023	
				July 1, 2020 to	
		U.S. Department of	P30CA033572-S3	November 30, 2021	
	Cancer Detection and	Health and Human		September 1, 2020 to	
	Diagnosis Research	Services	P50CA107399-S1	August 31, 2022	

91 2306-4265642

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance					
Listing					
Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
				July 1, 2019 to July 31,	
			R01CA227602	2024	
			100161011015	June 15, 2021 to May 31,	
			1R01CA241845	2026 July 1, 2016 to June 30,	C. I. I. Cl. II. I
			R01CA193478	2021	St. Jude Children's
			K01CA193476	2021	Research Hospital University of
				July 1, 2018 to June 30,	Nebraska Medical
			R01CA218545	2022	Center
				September 1, 2020 to	Mayo Clinic –
			R01CA237602	May 31, 2025	Jacksonville
					The Children's
				September 1, 2021 to	Hospital of
			R01CA254955	August 31, 2022	Philadelphia
					University of
				1 2022 4-	California San Diego Fetal Care and
			R01CA228147	January 1, 2022 to March 31, 2024	Genetics
			K01CA220147	September 20, 2021 to	Rensselaer
			R01CA250636	April 30, 2023	Polytechnic Institute
93,395			110101120000	September 3, 2014 to	1 officerinie Institute
			R01CA181045	August 31, 2021	
				September 1, 2015 to	
			R01CA198076	August 31, 2021	
				July 1, 2015 to June 30,	
			R01CA196854	2021	
			D01G10EEE44	December 1, 2015 to	
			R01CA077544	November 30, 2018	
			R01CA201184	December 3, 2015 to November 30, 2021	
			K01CA201104	April 1, 2016 to March 31,	
			R01CA201496	2022	
				February 16, 2017 to	
			R01CA213131	December 31, 2022	
				February 1, 2017 to	
			R01CA194742	August 31, 2023	
				January 16, 2017 to	
			R01CA139158	May 31, 2023	
			D01CA 1920C2	March 8, 2017 to July 31,	
			R01CA182963	2022 August 1, 2017 to July 31,	
			R01CA205247	2022	
			101011100211	January 1, 2018 to	
			R01CA211614	December 31, 2021	
				March 1, 2018 to	
		U.S. Department of	UM1CA186717	February 28, 2023	
	Cancer Treatment	Health and Human		September 1, 2018 to	
	Research	Services	R01CA215183	August 31, 2023	

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance Listing Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
	<u> </u>			December 1, 2018 to	
			R01CA233922	November 30, 2023	
				December 7, 2018 to	
			R21CA223141	November 30, 2021	
				January 1, 2019 to	
			R01CA236500	December 31, 2023	
				April 1, 2019 to March 31,	
			R01CA236626	2024	
			1101011200020	March 15, 2019 to	
			R01CA229510	February 29, 2024	
			101011229310	July 1, 2019 to June 30,	
			R21CA223400	2022	
			K21CA223400	June 1, 2019 to May 31,	
			R21CA229967	2022	
				June 1, 2019 to May 31,	
			U01CA239373	2024	
				August 1, 2019 to July 31,	
			R01CA238429	2024	
				August 1, 2019 to	
			R01CA227230	August 31, 2024	
				December 1, 2019 to	
			R01CA243386	November 30, 2024	
			R01CA154491	January 1, 2020 to December 31, 2024	
			R21CA241283	July 1, 2020 to June 30, 2022	
			R01CA236626-S1	August 12, 2020 to March 31, 2022	
			R01CA254271	August 1, 2020 to April 30, 2025	
			K01C/125+2/1	June 15, 2020 to	
			UM1CA186717-S1	February 28, 2023	
			001	February 1, 2021 to	
			R01CA244576	January 31, 2026	
			1101011211070	January 1, 2021 to	
			R01CA198128	March 31, 2023	
				January 1, 2021 to	
			R01CA246553	April 30, 2023	
			101011210333	May 1, 2021 to April 30,	
			R01CA253545	2026	
				July 9, 2021 to June 30,	
			R01CA265095	2026	
				July 9, 2021 to June 30,	
			R21CA263751	2023	
				September 21, 2021 to	
			R50CA252135	August 31, 2026	
				December 1, 2021 to	
			R21CA256593	November 30, 2023	

93

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance					
Listing					
Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
110222002	110814111111111111111111111111111111111	1 000101 0101101	121141412	January 1, 2022 to	1 tips till ough ontrey
			R21CA267570	December 31, 2023	
				March 1, 2022 to	
			R21CA270912	February 29, 2024	
				March 3, 2022 to	
			R21CA263223	February 29, 2024	
				January 1, 2022 to	
			R01CA266665	December 31, 2026	
				March 1, 2022 to	
			R01CA271497	February 28, 2027	
				September 13, 2021 to	
			U19CA264512	August 31, 2023	
				April 18, 2022 to	
			R01CA269569	March 31, 2027	
			D01G1070700	July 1, 2022 to June 30,	
			R01CA272732	2027	TT 1 1 0
			111001007160	April 1, 2010 to	University of
			U10CA027469	September 28, 2021	California, Irvine
			D01CA175216	July 1, 2016 to June 30, 2022	Seattle Children's Research Institute
			R01CA175216	August 1, 2016 to July 1,	Research institute
			R01CA201382	2022	Ohio State University
			K01CA201302	2022	University of
					California San Diego
				August 1, 2017 to July 31,	
			R01CA206911	2022	Genetics
					University of
				March 1, 2018 to	Nebraska Medical
			P01CA229100	August 31, 2023	Center
				September 18, 2018 to	Brigham and
			P01CA163205	August 31, 2023	Women's Hospital
				May 1, 2019 to April 30,	Mount Sinai School
			R01CA207446	2022	of Medicine
					University of
				December 20, 2019 to	Nebraska Medical
			R01CA247471	November 30, 2022	Center
				G . 1 . 10 .0013	University of
			IIII2C 4 20 C 127	September 12, 2019 to	Nebraska Medical
			UH3CA206127	August 31, 2022	Center
			112404247642	May 15, 2020 to April 30,	UPMC Hillman
			U24CA247643	2025 March 1, 2020 to	Cancer Center Oregon Health and
			U10CA180888	February 28, 2023	Science University
			U10CA100000	rebluary 28, 2023	The George
				May 1, 2021 to August 31,	Washington
			UM1CA181255	2022	University
			UNITCA 101233	2022	Oniversity

2306-4265642 94

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance Listing					
Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
			U01CA253218	September 20, 2021 to August 31, 2022	University of Nebraska Medical Center
			U01CA253216	September 22, 2021 to	Center
			R01CA262388	August 31, 2022	Ohio State University
			R01CA248381	July 1, 2021 to May 31, 2023	University of Southern California
			R01CA262292	June 1, 2022 to May 31, 2023	University of Wisconsin
			U24CA055727	May 10, 2022 to November 30, 2022	St. Jude Children's Research Hospital
			U10CA021661	January 1, 2010 to April 30, 2017	American College of Radiology
93.396			UH3CA213385	September 15, 2016 to August 31, 2022	
			R01CA155769	April 1, 2017 to March 31, 2022	
			R00CA201075	May 15, 2017 to October 31, 2020	
			R01CA214965	October 1, 2017 to December 31, 2022	
			R01CA228465	March 1, 2018 to February 28, 2023	
			R21CA232275	July 1, 2018 to June 30, 2021	
			R35CA210087	February 18, 2018 to June 30, 2024	
			R01CA236399	February 1, 2019 to January 31, 2024	
			R01CA068458	January 14, 2019 to July 31, 2021	
			U01CA232216	September 16, 2019 to August 31, 2024	
			R03CA245996	December 1, 2019 to November 30, 2021 December 1, 2019 to	
			R01CA247550	November 30, 2024 April 1, 2020 to March 31,	
			R01CA248475	2025 February 14, 2020 to	
			R01CA247368	January 31, 2025 March 1, 2020 to	
			R01CA248149	February 28, 2025 April 1, 2020 to March 31,	
	Cancer Biology	U.S. Department of Health and Human	R01CA240910	2025 May 1, 2020 to April 30,	
	Research	Services	U01CA250046	2025	

95

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance					
Listing Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
Number	110grain Title	reuci ai Giantoi	Awaru ID	July 8, 2021 to June 30,	1 ass-till ough entity
			R01CA255250	2026	
			1101011200200	July 1, 2021 to June 30,	
			R01CA262754	2026	
				September 1, 2021 to	
			U01CA264620	August 31, 2026	
				September 1, 2021 to	
			R01CA264911	August 31, 2026	
				December 1, 2021 to	
			R01CA258778	November 30, 2026	
				January 1, 2022 to	
			R01CA258981	August 31, 2026	
				4 111 2020 - 35 1 21	University of
			D01CA244000	April 1, 2020 to March 31,	Nebraska Medical
		•	R01CA244900	2023	Center University of
					California San Diego
				July 1, 2020 to June 30,	Fetal Care and
			R01CA212119	2022	Genetics
				September 1, 2019 to	Dana-Farber Cancer
			P01CA233412	August 31, 2022	Institute
					University of
				August 1, 2021 to July 31,	Nebraska Medical
			R01CA251412	2023	Center
				September 14, 2020 to	
			P01CA245705	June 30, 2025	Cleveland Clinic
				September 1, 2019 to	Northern California Institute for Research
			UG3 CA241703	August 31, 2023	and Education
			UG3 CA241703	September 22, 2021 to	University of
			R35 CA197699	July 31, 2022	California, San Diego
93.397				September 6, 2013 to	
			P50CA107399	August 31, 2023	
				October 1, 2017 to June 30,	
			U54CA209978	2023	
				April 1, 2018 to	
			P30CA033572	November 30, 2022	
			D20GA 022572 G2	December 1, 2018 to	
			P30CA033572-S2	November 30, 2022	
			P20CA242619	September 2, 2019 to August 31, 2023	
			F20CA242019	September 1, 2020 to	
		U.S. Department of	P30CA033572-S4	November 30, 2021	University of
	Cancer Centers	Health and Human	100011000012 DT	September 1, 2019 to	California, Los
	Support Grants	Services	P50CA092131	August 31, 2024	Angeles
93.398	Cancer Research			September 1, 2015 to	Johns Hopkins
	Manpower		R25CA183723	August 31, 2021	Medical Institutions

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance					
Listing	D (15:41	E L LC 4	4 1TD	4 187	D 41 1 44
Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
			T220CL 10 C005	July 14, 2016 to June 30,	
			T32CA186895	2027	
			T700G 1 201501	July 1, 2017 to June 30,	
			K08CA201591	2022	
			TT40G 1 004F0F	May 1, 2017 to July 31,	
			K12CA001727	2023	
				August 16, 2017 to July 31,	
			R25CA217270	2022	
				September 1, 2018 to	
			R25CA171998	August 31, 2023	
				September 1, 2018 to	
			T32CA221709	August 31, 2023	
				September 19, 2018 to	
			R25CA233431	February 29, 2024	
				March 6, 2020 to	
			R25CA240111	February 28, 2025	
				July 13, 2020 to June 30,	
			R00CA241297	2023	
				September 29, 2020 to	
			F32CA247311	September 28, 2023	
				December 1, 2021 to	
			R00CA256526	November 30, 2022	
				September 1, 2021 to	
			F31CA261110	August 31, 2023	
				August 6, 2021 to April 30,	
			K08CA245193	2023	
				January 1, 2021 to	
			F32CA254286	December 31, 2023	
				August 1, 2019 to July 31,	
			K99CA234391	2021	
				August 1, 2021 to July 31,	
		U.S. Department of	R00CA226387	2024	
		Health and Human		September 1, 2018 to	
		Services	R25CA225485	August 31, 2023	
93.399		U.S. Department of			Virginia
		Health and Human		September 20, 2021 to	Commonwealth
	Cancer Control	Services	P20CA252717	August 31, 2022	University
93.837				January 1, 2017 to	
			R01HL106089	April 30, 2025	
				July 1, 2019 to June 30,	
			R01HL145170	2024	
				September 27, 2019 to	
			OT3HL152932	September 26, 2023	
				February 1, 2020 to	
		U.S. Department of	R01HL150069	January 31, 2025	
	Cardiovascular	Health and Human		April 1, 2021 to	
	Diseases Research	Services	K08HL132110	September 30, 2021	

97 2306-4265642

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance					
Listing					
Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
				August 1, 2021 to June 30,	
			R03HL154300	2023	
			D047774###	September 1, 2021 to	
			R01HL157626	August 31, 2026	
			D011II 157051	March 1, 2022 to	
			R01HL156951	February 28, 2026 November 1, 2021 to	
			K08HL148540	July 31, 2025	
			KU011L140J4U	May 1, 2022 to June 30,	
			R01HL137723	2023	
			ROTHETS/723	August 1, 2016 to	
			P01HL129941	November 30, 2021	Vanderbilt University
					University of
					California San Diego
				August 1, 2017 to July 31,	Fetal Care and
			R01HL108735	2022	Genetics
				February 1, 2018 to	
			R35HL140016	December 31, 2022	Vanderbilt University
				July 1, 2020 to June 30,	University of
			R21HL150723	2022	Pennsylvania
			D251H 15000F	June 1, 2020 to May 31,	Massachusetts
			R35HL150807	2022	General Hospital
			DO1111 147545	August 17, 2020 to	University of Iowa –
			R01HL147545	March 31, 2023 January 1, 2022 to	Pathology
			R01HL153112	December 31, 2025	University Of Arizona
93.838			ROTHETSSTIE	January 1, 2019 to	Chrycisity Of Amzona
75.050			R01HL145372	December 31, 2023	
				July 13, 2020 to	
		U.S. Department of	R01HL132177	December 31, 2021	University of Virginia
	Lung Diseases	Health and Human		January 1, 2022 to	University of
	Research	Services	R01HL114959	December 31, 2022	Southern California
93.839				July 27, 2017 to June 30,	
			UG1HL069278	2023	
				March 3, 2018 to	
			R01HL141336	February 28, 2023	
			DO1HI 141270	September 15, 2018 to	
			R01HL141379	June 30, 2022 May 15, 2019 to April 30,	
			R01HL146632	2022 May 15, 2019 to April 30,	
			K0111L140032	February 4, 2021 to	
			R01HL146632-S1	April 30, 2021	
				September 1, 2017 to	
			R01HL111656	April 30, 2022	Indiana University
				June 5, 2019 to June 5,	National Marrow
		U.S. Department of	1703	2024	Donor Program
	Blood Diseases and	Health and Human		June 5, 2019 to June 5,	National Marrow
	Resources Research	Services	1702	2024	Donor Program

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance					
Listing					
Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
93.847				September 1, 2016 to	
			R01DK097837	August 31, 2020	
				September 1, 2017 to	
			R01DK112041	June 30, 2023	
				December 1, 2017 to	
			R01DK112794	November 30, 2022	
				June 1, 2018 to May 31,	
			R01DK112917	2023	
				July 1, 2018 to June 30,	
			R01DK065073	2023	
				September 15, 2018 to	
			R01DK119590	July 31, 2023	
				April 1, 2019 to	
			R01DK120523	January 31, 2024	
				July 1, 2019 to June 30,	
			U24DK104162	2024	
				September 13, 2019 to	
			U24DK085532	August 31, 2024	
				September 11, 2019 to	
			R01DK067912	July 31, 2024	
				July 1, 2017 to October 15,	
			UC4DK098085	2022	
				March 10, 2020 to	
			R01DK124116	December 31, 2023	
			D01D11001505	July 21, 2020 to June 30,	
			R01DK081705	2024	
			114201/005522 01	September 1, 2020 to	
			U42DK085532-S1	August 31, 2023	
			D01DW107005	September 15, 2020 to	
			R21DK127285	July 31, 2023	
			D01DW104607	September 14, 2020 to	
			R01DK124627	May 31, 2025	
			D01DW10222	December 3, 2020 to	
			R01DK102233	November 30, 2024	
			R56DK129332	July 1, 2021 to June 30, 2023	
			K30DK129332	September 16, 2021 to	
			U24DK098085	September 15, 2021 to September 15, 2026	
			U24DR030003	July 15, 2021 to May 31,	
			R01DK104941	2025	
			KU1DK1U4741	August 1, 2021 to July 31,	
			R01DK126975	2025	
			K01DK1207/3	August 4, 2021 to April 30,	
			R03DK129958	2023	
			R03DR12//30	August 24, 2021 to	
	Diabetes, Digestive,	U.S. Department of	R01DK125856	May 31, 2025	
	and Kidney Diseases	Health and Human	10121112000	August 1, 2017 to July 31,	
	Extramural Research	Services	R01DK107735	2022	
	Latamara Research	DCI VICCO	ROIDINIOTISS	2022	

99

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance					
Listing Number	Program Title	Federal Grantor	A 1 TD	A J V/	Pass-through entity
Number	Program Title	rederal Grantor	Award ID	Award Year June 1, 2019 to July 31,	Pass-through entity
			R01DK107735-03S1	2022	
			K01DK107733-0331	August 20, 2019 to July 31,	
			R01DK120890	2025	
			1101211120070	April 15, 2022 to	
			R01DK127015	February 28, 2027	
					University of
				March 5, 2020 to July 17,	Minnesota Medical
			R01DK121019	2022	Center
			**************************************	November 1, 2020 to	
			U24DK076169	October 31, 2021	Augusta University
			D42DW117702	December 1, 2019 to	21st Century
			R43DK117782	July 31, 2022 April 15, 2021 to	Medicine
			R01DK128907	March 31, 2023	Tulane University
			K01DK120907	September 1, 2021 to	University of
			R01DK130499	June 30, 2022	Pittsburgh
				July 1, 2021 to June 30,	
			U24DK115255	2022	University of Utah
					University of
					California San Diego
				September 1, 2021 to	Fetal Care and
			R01DK114945	August 31, 2022	Genetics
93.853			D01NG007120	March 15, 2016 to	
			R01NS096130	February 28, 2021 March 5, 2019 to	
			R01NS106170	November 30, 2022	
			K011\5100170	June 15, 2021 to May 31,	
			U01NS122101	2023	
			0.000.000000000000000000000000000000000	September 30, 2020 to	University of
			R56NS113810	August 31, 2021	Pittsburgh
				June 15, 2021 to March 31,	Virginia Polytechnic
			R01NS115971	2022	Institute and State
				September 1, 2021 to	University of
			R01NS121037	August 31, 2022	Pittsburgh
				S . 1 . 1 2021 .	Saint Joseph's
			R01NS120331	September 1, 2021 to August 31, 2026	Hospital and Medical Center
			K011N312U331	August 31, 2020	Saint Joseph's
				September 1, 2020 to	Hospital and Medical
			R21NS116385	May 31, 2023	Center
	Extramural Research			<u>*</u>	Saint Joseph's
	Programs in the			September 29, 2021 to	Hospital and Medical
	Neurosciences and	U.S. Department of	R21NS125861	March 19, 2023	Center
	Neurological	Health and Human	D041755	September 1, 2015 to	
02.055	Disorders	Services	R01NS091299	May 31, 2022	University of Arizona
93.855			DO1 A IO 42552	July 1, 2011 to July 31,	
			R01AI042552	2021	

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance					
Listing Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
Number	1 Togram Tue	reuci ai Giantoi	Awaiu iD	July 1, 2011 to	1 ass-till ough chuty
			R01AI096169	December 31, 2019	
			Rollinoyoloy	June 15, 2016 to	
			R01AI125615	September 30, 2021	
				May 1, 2019 to April 30,	
			R01AI109644	2024	
				March 4, 2019 to June 30,	
			R01AI129582	2023	
				August 13, 2020 to July 31,	
			R56AI147684	2021	
				September 8, 2020 to	
			R56AI148295	August 31, 2022	
				September 17, 2020 to	
			R01AI146313	August 31, 2025	
			D01 A T1 5 1 0 1 2	March 22, 2021 to	
			R01AI151013	February 28, 2026	
			D56 A 1066000	June 1, 2021 to May 31,	
			R56AI066008	2022 August 1, 2021 to July 31,	
			R21AI163256	2022	
			R21711103230	July 6, 2021 to June 30,	
			R21AI161075	2022	
				February 1, 2021 to	
			R21AI149311	July 31, 2022	
				March 16, 2020 to	
			R21AI149660	February 28, 2023	
				April 1, 2021 to March 31,	
			U24AI152172	2022	
				April 1, 2022 to March 31,	
			U24AI152172-03S1	2023	
				April 1, 2012 to March 31,	Scripps Research
			P01AI099783	2016	Institute
				A	University of
			U19AI128913	August 1, 2017 to July 31, 2022	California, Los Angeles
			U19A1128913	July 11, 2018 to June 30,	Cedars-Sinai Medical
			R01AI134714	2022	Center Center
			101/11137/17	2022	University of
				December 1, 2020 to	California, Los
			UM1AI068636	November 30, 2027	Angeles
				March 2, 2021 to	The J. David
			R37AI109593	February 28, 2023	Gladstone Institutes
				September 1, 2021 to	University of
	Allergy and	U.S. Department of	U01AI163090	May 31, 2023	Washington
	Infectious Diseases	Health and Human		August 1, 2021 to	Children's Hospital
	Research	Services	U24AI152179	March 31, 2023	Boston

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance					
Listing					
Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
				14 1 1 2016	University of
			DO1AT121144	March 1, 2016 to February 28, 2022	California, San Francisco
			R01AI121144	February 28, 2022	
				January 19, 2018 to	University of California, San
			R01AI131939	December 31, 2022	Francisco
			K01AI131737	December 31, 2022	University of
				March 1, 2021 to	California, San
			R01AI153213	February 28, 2026	Francisco
					University of
				September 1, 2020 to	California, San
			R21AI152564	August 31, 2022	Francisco
				August 22, 2019 to July 31,	University of Cape
			R01AI147346	2023	Town
				August 1, 2020 to July 31,	
			R01AI147854	2024	Yale University
93.859				May 17, 2017 to	
			R01GM117923	January 31, 2025	
			D01CM127602	May 1, 2018 to March 31,	
			R01GM127602	2023 August 1, 2018 to July 31,	
			R01GM129863	August 1, 2018 to July 31, 2022	
			K01GW129803	August 1, 2019 to April 30,	
	Biomedical Research	U.S. Department of	R01GM133850	2024	
	and Research	Health and Human	101011133030	May 1, 2021 to March 31,	Virginia Polytechnic
	Training	Services	R01GM141096	2023	Institute and State
93.865				April 14, 2020 to	
	Child Health and	U.S. Department of	R01HD096152	February 28, 2025	
	Human Development	Health and Human		April 6, 2020 to March 31,	
	Extramural Research	Services	K99HD099307	2022	N/A
93.866				August 1, 2017 to April 30,	
			R01AG056305	2023	
			D00 + G07000 4	April 1, 2018 to March 31,	
			R33AG059206	2023	
			RF1AG061794	September 30, 2018 to March 31, 2023	
			KI1AG001794	December 1, 2018 to	
			K24AG055693	November 30, 2022	
			112 1/10033073	July 15, 2019 to June 30,	
			R56AG061171	2021	
				August 1, 2019 to	
			R03AG064377	March 31, 2022	
				August 1, 2019 to	
			R03AG064376	March 31, 2022	
				September 1, 2019 to	
		U.S. Department of	R21AG059206	February 29, 2020	
		Health and Human	B04 + G0 <00 = :	May 15, 2020 to April 30,	
	Aging Research	Services	R01AG063854	2025	

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Identification of the federal program (continued):

Assistance					
Listing					
Number	Program Title	Federal Grantor	Award ID	Award Year	Pass-through entity
				July 1, 2022 to June 30,	
			R03AG077406	2024	
				September 15, 2019 to	
			UH2AG064706	August 31, 2023	
				September 15, 2019 to	
			UH3AG064706-03S1	August 31, 2022	
				September 30, 2021 to	
			R01AG072291	May 31, 2026	5
			DO4 1 GO 40500	August 1, 2018 to	Brigham and
			R01AG060539	December 18, 2020	Women's Hospital
				August 1, 2019 to	
			U01AG034661	March 31, 2023	Duke University
			11112 1 005 (022	September 1, 2020 to	Johns Hopkins
			UH3AG056933	August 31, 2023	Medical Institutions
			DO1 A CO50627	September 15, 2018 to	Arizona State
			R01AG059627	May 31, 2023	University
			D20 A C010 (10	September 30, 2001 to	D II 14h
			P30AG019610	December 31, 2021 September 5, 2021 to	Banner Health
			P30AG072980	June 30, 2026	Banner Health
			F30AG072980	September 30, 2020 to	Danner Health
			R01AG069453	March 31, 2026	Banner Health
			K01AG009433	Water 31, 2020	California Pacific
				September 30, 2004 to	Medical Center
			U19 AG023122	May 31, 2023	Research Institute
			01)110023122	May 15, 2017 to April 30,	research institute
			R01AG054180	2022	Jackson Laboratory
			1101110001100	May 1, 2020 to January 31,	Northwestern
			R01AG067781	2025	University
				September 30, 2021 to	Northwestern
			U19AG073153	May 31, 2026	University
				<u> </u>	The University of
				January 15, 2022 to	Alabama at
			R01AG075059	November 30, 2022	Birmingham
				May 1, 2021 to April 30,	
			R01AG072643	2026	University of Arizona
				September 15, 2020 to	
			R56AG068098	March 31, 2022	University of Arizona
				September 30, 2021 to	
			U19AG065169	August 31, 2026	University of Arizona
				September 1, 2018 to	
			R01AG057764	June 30, 2023	University of Florida
93.867		U.S. Department of			
		Health and Human	D045777777	September 30, 2018 to	University Of New
00.050	Vision Research	Services	R01EY028606	July 31, 2023	Mexico
93.879	3.6 11 1.7 1	U.S. Department of		I 1 1 2020 / I 21	
	Medical Library	Health and Human	D011 M012120	July 1, 2020 to January 31,	NT/A
	Assistance	Services	R01LM013138	2024	N/A

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Criteria or specific requirement (including statutory, regulatory or other citation):

Title 2, Subtitle A, Chapter II, Part 200, Subpart D, 200.303 – Internal controls. The non-Federal entity must: (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in "Standards for Internal Control in the Federal Government" issued by the Comptroller General of the United States or the "Internal Control Integrated Framework", issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Title 2, Subtitle A, Chapter II, Part 200, Subpart D, 200.318(i) – General procurement standards states: The non-Federal entity must maintain records sufficient to detail the history of procurement. These records will include, but are not necessarily limited to, the following: Rationale for the method of procurement, selection of contract type, contractor selection or rejection, and the basis for the contract price.

Title 2, Subtitle A, Chapter II, Part 200, Subpart D, 200.320 – Methods of procurement to be followed - the non-Federal entity must have and use documented procurements procedures, consistent with the standards of this section and 200.317, 200.318, and 200.319 for any of the following methods of procurement used for the acquisition of property or services required under a Federal award or sub-award: (a) (2) Small purchases - (i) small purchase procedures - the acquisition of property or services, the aggregate dollar amount of which is higher than the micropurchase threshold but does not exceed the simplified acquisition threshold. If small purchase procedures are used, price or rate quotations must be obtained from an adequate number of qualified sources as determined appropriate by the non-Federal entity; (b) Formal procurement methods – when the value of the procurement for property or services under a Federal financial assistance award exceeds the simplified acquisition threshold, formal procurement methods are required. Formal procurement methods require following documented procedures. The following formal methods of procurement are used for procurement of property or services above the simplified acquisition threshold – (1) sealed bids – a procurement method in which bids are publicly solicited and a firm fixed-price contract (lump sum or unit price) is awarded to the responsible bidder whose bid, conforming with all the material terms and conditions of the invitation for bids, is the lowest in price; (2) proposals – a procurement method in which either a fixed price or cost-reimbursement type contract is awarded.

104

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Criteria or specific requirement (including statutory, regulatory or other citation) (continued):

Title 2, Subtitle A, Chapter II, Part 200, Subpart C 200.214 – Suspension and debarment – Non-Federal entities are subject to the non-procurement debarment and suspension regulations that restrict awards, subawards, and contracts with certain parties that are debarred, suspended, or otherwise excluded from or ineligible for participation in Federal assistance programs or activities.

Condition:

During our testing over small purchase procurements and formal procurement methods, we observed management did not have effective internal controls in place to ensure that price or rate quotations were obtained from an adequate number of qualified sources at the time of procurement and sealed bids or proposals were obtained. In addition, during our testing over suspension and debarment, we observed management did not have effective internal controls in place to ensure vendors with covered transactions greater than \$25,000 were not suspended or debarred.

Cause:

Management did not have effective internal controls in place over the compliance requirement as stated in the criteria or specific requirement section above.

Effect or potential effect:

Small purchase procurements and formal procurement methods were not supported by effective internal controls and could potentially include unreasonable prices or rates. In addition, if a search for suspension and debarment is not conducted, the entity could contract with vendors that are suspended or debarred.

105

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Questioned costs:

\$560,068 – Assistance Listing Numbers 10.025, 10.310, 12.351, 12.420, 12.910, 93.103, 93.113, 93.121, 93.172, 93.226, 93.242, 93.273, 93.286, 93.301, 93.307, 93.310, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.398, 93.399, 93.837, 93.838, 93.839, 93.847, 93.853, 93.855, 93.865, 93.866, 93.867, 93.879. See corresponding award identification numbers in the identification of federal award section above.

Questioned costs were computed by taking the total small purchase procurements, formal procurements, and suspension and debarment procurements that were not supported by adequate documentation of \$196,639 (\$54,000 + \$28,560 + \$114,079), \$300,300, and \$63,129, respectively for a total of \$560,068.

Context:

Testing over procurement and suspension and debarment were performed over City of Hope and Translational Genomics Research Institute separately as they operate under different internal control environments.

During our testing over small purchase procurements for City of Hope, we obtained a listing of 26 small purchase procurements and selected a sample of 5. The total value of the 5 small purchases selected was \$282,719 out of the total population of \$1,510,159.

There was 1 (\$54,000) out of 5 (\$282,719) selections where management didn't follow its procurement policy to fill out the "Supplier Selection Justification" form, which is required to be completed for all small purchase procurements.

There was 1 (\$28,560) out of 5 (\$282,719) selections where price or rate quotations were not obtained from an adequate number of qualified sources at the time of procurement.

There were 2 (\$114,079) out of 5 (\$282,719) selections where management didn't follow its procurement policy to evaluate existing contracts at the end of the contract term.

During our testing over formal procurements for City of Hope, we obtained a listing of 2 formal procurements and selected a sample of 2. The total value of the 2 formal procurements were \$663,744.

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Context (continued):

There was 1 (\$300,300) out of 2 (\$663,744) selections where management didn't follow its procurement policy to evaluate existing contracts at the end of the contract term.

During our testing over suspension and debarment for Translational Genomics Research Institute, we obtained a listing of 18 vendors with covered transactions greater than \$25,000 and selected a sample of 6. The total value of the 6 vendors selected was \$244,467 out of the total population of \$1,332,111.

There was 1 (\$63,129) out of 6 (\$244,467) selections where a search for suspension and debarment was not completed.

Identification as a repeat finding, if applicable:

No.

Recommendation:

We recommend that management develop and implement effective internal controls to ensure small purchase procurements were supported by price or rate quotations from an adequate number of qualified suppliers, formal methods of procurement included sealed bids or proposals, and vendors with covered transactions greater than \$25,000 were not suspended or debarred.

Views of responsible officials:

In response to this finding City of Hope will implement the following:

- 1. Procurement Operations to provide training to reinforce current policy requirements. Training will also include Strategic Sourcing and Research personnel to emphasize procurement guidelines prior to requisition submission.
- 2. Corporate Accounting will select a sample size of federally funded procurement spend to ensure controls have been appropriately remediated.
- 3. Procurement and Sourcing department will review current long-term contracts pertaining to federal funding to ensure adherence with documented compliance standards.

Schedule of Findings and Questioned Costs (continued)

Year Ended September 30, 2022

Section III – Federal Award Findings and Questioned Costs (continued)

Views of responsible officials (continued):

- 4. To ensure controls are operating effectively around suspension and debarment reviews, finance leadership will work with the purchasing department to update internal control policies to confirm there is a full review of all vendors engaged to work on federally funded programs.
- 5. Purchasing department will perform a review of existing contracts to ensure suspension and debarment reviews have been completed.

EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2023 Ernst & Young LLP. All Rights Reserved.

ey.com





Management's Corrective Action Plan

In response to this finding City of Hope will implement the following:

- 1. Procurement Operations to provide training to reinforce current policy requirements. Training will also include Strategic Sourcing and Research personnel to emphasize procurement guidelines prior to requisition submission.
- 2. Corporate Accounting will select a sample size of federally funded procurement spend to ensure controls have been appropriately remediated.
- 3. Procurement and Sourcing department will review current long-term contracts pertaining to federal funding to ensure adherence with documented compliance standards.
- 4. To ensure controls are operating effectively around suspension and debarment reviews, finance leadership will work with the purchasing department to update internal control policies to confirm there is a full review of all vendors engaged to work on federally funded programs.
- 5. Purchasing department will perform a review of existing contracts to ensure suspension and debarment reviews have been completed.

Contact Person:

Ryan Cabarrao, System Vice President, Sourcing and Procurement (Actions 1, 2, and 3) Tracy Karns, TGen Controller (Action 4 and 5)

Expected Completion Date: September 30, 2023